{
  "NCT06472557": {
    "nct_id": "NCT06472557",
    "brief_title": "Spinocerebellar Ataxia Type 27B Natural History Study (SCA27B-NHS)",
    "official_title": "Spinocerebellar Ataxia Type 27B Natural History Study (SCA27B-NHS)",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 300,
    "diseases": [
      {
        "orpha_code": "101109",
        "disease_name": "Spinocerebellar ataxia type 28"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-06-27"
  },
  "NCT06953583": {
    "nct_id": "NCT06953583",
    "brief_title": "A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old",
    "official_title": "A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled Study (Part 1) and Open-Label Extension (Part 2) to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omaveloxolone (BIIB141) in Participants With Friedreich's Ataxia Aged 2 to < 16 Years",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Omaveloxolone"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 255,
    "diseases": [
      {
        "orpha_code": "101109",
        "disease_name": "Spinocerebellar ataxia type 28"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-19"
  },
  "NCT06056297": {
    "nct_id": "NCT06056297",
    "brief_title": "A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections",
    "official_title": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Mavorixafor"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 150,
    "diseases": [
      {
        "orpha_code": "111",
        "disease_name": "Barth syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-17"
  },
  "NCT01797055": {
    "nct_id": "NCT01797055",
    "brief_title": "Apotransferrin in Atransferrinemia",
    "official_title": "Dose Escalating Study to Evaluate Pharmacokinetics, Efficacy and Safety of Apotransferrin in Atransferrinemia Patients",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Human apotransferrin"
      }
    ],
    "enrollment": 5,
    "diseases": [
      {
        "orpha_code": "1195",
        "disease_name": "Congenital atransferrinemia"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-07-16"
  },
  "NCT06362486": {
    "nct_id": "NCT06362486",
    "brief_title": "Stress in Pregnancy During the Covid19 Pandemic and Impact on the Newborn Neurodevelopment",
    "official_title": "Stress in Pregnancy During the Covid19 Pandemic and Impact on the Newborn Neurodevelopment",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "OTHER",
        "name": "Severity of infection, time of infection."
      },
      {
        "type": "OTHER",
        "name": "Mental health assessment"
      },
      {
        "type": "OTHER",
        "name": "biological"
      }
    ],
    "enrollment": 1000,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-04-12"
  },
  "NCT06392386": {
    "nct_id": "NCT06392386",
    "brief_title": "A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age with Generalized Myasthenia Gravis",
    "official_title": "An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants from 2 to Less Than 18 Years of Age with Generalized Myasthenia Gravis",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "Efgartigimod PH20 SC"
      }
    ],
    "enrollment": 12,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-04"
  },
  "NCT06021522": {
    "nct_id": "NCT06021522",
    "brief_title": "A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder",
    "official_title": "A Multicenter, Open-Label, Study to Evaluate the Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Ecopipam"
      }
    ],
    "enrollment": 150,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-22"
  },
  "NCT06197035": {
    "nct_id": "NCT06197035",
    "brief_title": "The Coping With and Caring for Infants With Special Needs Intervention in Down Syndrome Infants",
    "official_title": "Coping and Caring for Families With Babies With Down Syndrome. A Family-centered Intervention",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "PROCEDURE",
        "name": "Coping With and Caring for Infants With Special Needs"
      },
      {
        "type": "PROCEDURE",
        "name": "Standard Physiotherapy"
      }
    ],
    "enrollment": 40,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-04-01"
  },
  "NCT05216835": {
    "nct_id": "NCT05216835",
    "brief_title": "Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma",
    "official_title": "A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Sabestomig (AZD7789)"
      }
    ],
    "enrollment": 45,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-02"
  },
  "NCT05723835": {
    "nct_id": "NCT05723835",
    "brief_title": "A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9",
    "official_title": "A Study Evaluating the Safety and Efficacy of Once-weekly Dosing of Somapacitan in a Basket Study Design in Paediatric Participants With Short Stature Either Born Small for Gestational Age or With Turner Syndrome, Noonan Syndrome or Idiopathic Short Stature",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Somapacitan"
      }
    ],
    "enrollment": 47,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-30"
  },
  "NCT05942924": {
    "nct_id": "NCT05942924",
    "brief_title": "The NEU-STIM Trial",
    "official_title": "A Randomised Trial of Repetitive Versus Selective Tactile Stimulation for Preterm Infants at Birth: The NEU-STIM Trial",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "PROCEDURE",
        "name": "Repeated tactile stimulation"
      },
      {
        "type": "PROCEDURE",
        "name": "Selective tactile stimulation"
      }
    ],
    "enrollment": 3280,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-10"
  },
  "NCT05317416": {
    "nct_id": "NCT05317416",
    "brief_title": "Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant",
    "official_title": "A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Elranatamab"
      },
      {
        "type": "DRUG",
        "name": "Lenalidomide"
      },
      {
        "type": "DRUG",
        "name": "Lenalidomide"
      },
      {
        "type": "DRUG",
        "name": "Elranatamab"
      }
    ],
    "enrollment": 760,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-02"
  },
  "NCT05522374": {
    "nct_id": "NCT05522374",
    "brief_title": "TIRCON International NBIA Registry",
    "official_title": "TIRCON International NBIA (Neurodegeneration Associated With Brain Iron Accumulation) Patient Registry and Natural History Study",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 2000,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      },
      {
        "orpha_code": "157846",
        "disease_name": "Neuroferritinopathy"
      },
      {
        "orpha_code": "157850",
        "disease_name": "Pantothenate kinase-associated neurodegeneration"
      },
      {
        "orpha_code": "329308",
        "disease_name": "Fatty acid hydroxylase-associated neurodegeneration"
      },
      {
        "orpha_code": "35069",
        "disease_name": "Infantile neuroaxonal dystrophy"
      },
      {
        "orpha_code": "48818",
        "disease_name": "Aceruloplasminemia"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-05"
  },
  "NCT04528082": {
    "nct_id": "NCT04528082",
    "brief_title": "Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease",
    "official_title": "A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Apremilast"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 60,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-20"
  },
  "NCT05630066": {
    "nct_id": "NCT05630066",
    "brief_title": "A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.",
    "official_title": "A Phase IIa Multicenter, Open-label, 12-week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Alogabat"
      }
    ],
    "enrollment": 56,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-29"
  },
  "NCT05627557": {
    "nct_id": "NCT05627557",
    "brief_title": "A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome",
    "official_title": "A Phase III, International, Multicenter, Randomised Open Label Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Patients With Childhood Onset Idiopathic Nephrotic Syndrome",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Obinutuzumab"
      },
      {
        "type": "DRUG",
        "name": "MMF"
      },
      {
        "type": "DRUG",
        "name": "Prednisone"
      },
      {
        "type": "DRUG",
        "name": "Methylprednisolone"
      },
      {
        "type": "DRUG",
        "name": "Acetaminophen/ Paracetamol"
      },
      {
        "type": "DRUG",
        "name": "Diphenhydramine Hydrochloride"
      }
    ],
    "enrollment": 80,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-02"
  },
  "NCT05101148": {
    "nct_id": "NCT05101148",
    "brief_title": "Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas",
    "official_title": "A Phase I, Single-Arm, Sequential Study to Evaluate the Effect of Food on the Gastrointestinal Tolerability and Pharmacokinetics of Selumetinib After Multiple Doses in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Selumetinib"
      }
    ],
    "enrollment": 24,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-09"
  },
  "NCT04797260": {
    "nct_id": "NCT04797260",
    "brief_title": "Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID",
    "official_title": "Phase I/II Clinical Trial of Autologous Hematopoietic Stem Cell Gene Therapy in RAG1-Deficient Severe Combined Immunodeficiency",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "GENETIC",
        "name": "Gene therapy"
      }
    ],
    "enrollment": 10,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-04-18"
  },
  "NCT06574399": {
    "nct_id": "NCT06574399",
    "brief_title": "Identification and Validation of Clinical Phenotypes in Staphylococcus Aureus Bacteremia and Their Association With Mortality and Development of Complicated Bacteremia",
    "official_title": "Identification and Validation of Clinical Phenotypes in Staphylococcus Aureus Bacteremia and Their Association With Mortality and Development of Complicated Bacteremia",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 1000,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-08-27"
  },
  "NCT05846126": {
    "nct_id": "NCT05846126",
    "brief_title": "Digital Multimodal Rehabilitation for People With Post-acute COVID-19 Syndrome.",
    "official_title": "Digital Rehabilitation With Cognitive Training, Physical Activity and Mindfulness for People With Post-acute COVID-19 Syndrome With Cognitive Impairment. REHABCOVID Project.",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "BEHAVIORAL",
        "name": "RehabCovid_Telematic"
      },
      {
        "type": "BEHAVIORAL",
        "name": "RehabCovid_ImmersiveVR"
      },
      {
        "type": "BEHAVIORAL",
        "name": "Control_Condition"
      }
    ],
    "enrollment": 158,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-09-19"
  },
  "NCT03915366": {
    "nct_id": "NCT03915366",
    "brief_title": "Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia",
    "official_title": "Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia: a Multicenter, Open-label Randomized Controlled Clinical Trial",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Valganciclovir Oral Solution [Valcyte]"
      },
      {
        "type": "DRUG",
        "name": "Tuberculostatic Agents"
      }
    ],
    "enrollment": 563,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-02-09"
  },
  "NCT04766866": {
    "nct_id": "NCT04766866",
    "brief_title": "sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.",
    "official_title": "Protocol of the PE37 Study: A Multicenter Randomized Trial of Screening With sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "DIAGNOSTIC_TEST",
        "name": "sFlt1/PlGF screening in maternal blood at 35 to 36.6 weeks of gestation"
      }
    ],
    "enrollment": 9132,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-02-19"
  },
  "NCT00825929": {
    "nct_id": "NCT00825929",
    "brief_title": "Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.",
    "official_title": "Study on Pharmacokinetics of Newly Developed ANtiretroviral Agents in HIV-infected pregNAnt Women (PANNA)",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 176,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-01-13"
  },
  "NCT05661331": {
    "nct_id": "NCT05661331",
    "brief_title": "VIATORR Device Registry",
    "official_title": "VIATORR Device Registry - Post-Market Clinical Follow-Up (PMCF) Registry of the GORE® VIATORR® TIPS Endoprosthesis With Controlled Expansion to Treat Portal Hypertension and Its Complications",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "DEVICE",
        "name": "Transjugular intrahepatic portosystemic shunt"
      }
    ],
    "enrollment": 196,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-24"
  },
  "NCT02066220": {
    "nct_id": "NCT02066220",
    "brief_title": "International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma",
    "official_title": "AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB - LR and PNET 5 MB - WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR), OR TP53 MUTATION, AND REGISTRY FOR MB OCCURRING IN THE CONTEXT OF GENETIC PREDISPOSITION",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "RADIATION",
        "name": "Radiotherapy without Carboplatin"
      },
      {
        "type": "DRUG",
        "name": "Reduced-intensity maintenance chemotherapy"
      },
      {
        "type": "RADIATION",
        "name": "Radiotherapy with Carboplatin"
      },
      {
        "type": "DRUG",
        "name": "Maintenance chemotherapy"
      },
      {
        "type": "RADIATION",
        "name": "WNT-HR < 16 years"
      },
      {
        "type": "RADIATION",
        "name": "WNT-HR >= 16 years"
      },
      {
        "type": "DRUG",
        "name": "Induction Chemotherapy"
      },
      {
        "type": "RADIATION",
        "name": "SHH-TP53 M0"
      },
      {
        "type": "RADIATION",
        "name": "SHH-TP53 M+ (germline)"
      },
      {
        "type": "RADIATION",
        "name": "SHH-TP53 (somatic)"
      },
      {
        "type": "DRUG",
        "name": "Vinblastin Maintenance"
      }
    ],
    "enrollment": 360,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2022-04-19"
  },
  "NCT05386173": {
    "nct_id": "NCT05386173",
    "brief_title": "Effect of Fetal Aortic Valvuloplasty on Outcomes",
    "official_title": "Effect of Fetal Aortic Valvuloplasty on Outcomes. A Prospective Observational Cohort Study With a Comparison Cohort",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "PROCEDURE",
        "name": "Fetal aortic balloon dilatation"
      }
    ],
    "enrollment": 200,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-21"
  },
  "NCT03635073": {
    "nct_id": "NCT03635073",
    "brief_title": "A Study of Soticlestat in Adults and Children With Rare Epilepsies",
    "official_title": "A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of Soticlestat (TAK-935) as Adjunctive Therapy in Subjects With Developmental Epileptic Encephalopathies Including Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome (ENDYMION 1)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Soticlestat"
      }
    ],
    "enrollment": 156,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-30"
  },
  "NCT03486873": {
    "nct_id": "NCT03486873",
    "brief_title": "Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)",
    "official_title": "A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Pembrolizumab"
      },
      {
        "type": "DRUG",
        "name": "Standard of Care (SOC)"
      },
      {
        "type": "DRUG",
        "name": "Lenvatinib"
      },
      {
        "type": "DRUG",
        "name": "Olaparib"
      },
      {
        "type": "DRUG",
        "name": "MK-4280"
      },
      {
        "type": "BIOLOGICAL",
        "name": "MK-4280A"
      }
    ],
    "enrollment": 3500,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      },
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-19"
  },
  "NCT05965427": {
    "nct_id": "NCT05965427",
    "brief_title": "Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV",
    "official_title": "Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "OTHER",
        "name": "No intervention"
      }
    ],
    "enrollment": 2000,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-05-09"
  },
  "NCT04833894": {
    "nct_id": "NCT04833894",
    "brief_title": "Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children with Generalized Myasthenia Gravis",
    "official_title": "Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children from 2 to Less Than 18 Years of Age with Generalized Myasthenia Gravis",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "Efgartigimod IV"
      }
    ],
    "enrollment": 12,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-10-30"
  },
  "NCT05693129": {
    "nct_id": "NCT05693129",
    "brief_title": "Pediatric Patients Aged 1 to 6 Years With APDS",
    "official_title": "An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 1 to 6 Years) With APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed by an Open-label Long-term Extension",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Leniolisib"
      }
    ],
    "enrollment": 16,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-23"
  },
  "NCT05477589": {
    "nct_id": "NCT05477589",
    "brief_title": "Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML",
    "official_title": "A Randomized, Multi-Center Phase III Trial Comparing Two Conditioning Regimens (CloFluBu and BuCyMel) in Children With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "busulfan, cyclophosphamide and melphalan, BuCyMel"
      },
      {
        "type": "DRUG",
        "name": "clofarabine, fludarabine and busulfan, CloFluBu"
      }
    ],
    "enrollment": 170,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-12-19"
  },
  "NCT06660394": {
    "nct_id": "NCT06660394",
    "brief_title": "A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)",
    "official_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults With Dravet Syndrome",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "LP352"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 160,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-13"
  },
  "NCT05218655": {
    "nct_id": "NCT05218655",
    "brief_title": "A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease",
    "official_title": "An Open-Label, Safety Study for Previously Treated Vatiquinone (PTC743) Subjects With Inherited Mitochondrial Disease",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Vatiquinone"
      }
    ],
    "enrollment": 102,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      },
      {
        "orpha_code": "166073",
        "disease_name": "Pontocerebellar hypoplasia type 6"
      },
      {
        "orpha_code": "506",
        "disease_name": "Leigh syndrome"
      },
      {
        "orpha_code": "550",
        "disease_name": "MELAS"
      },
      {
        "orpha_code": "551",
        "disease_name": "MERRF"
      },
      {
        "orpha_code": "726",
        "disease_name": "Alpers-Huttenlocher syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-04"
  },
  "NCT06258512": {
    "nct_id": "NCT06258512",
    "brief_title": "Impact of an Intervention with a Narrative Approach in Overusers: a Clinical Trial",
    "official_title": "Impact of an Intervention with a Narrative Approach in Overusers in Primary Health Care: a Controlled and Randomized Trial",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "OTHER",
        "name": "Intervention with a narrative approach."
      }
    ],
    "enrollment": 264,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-08-26"
  },
  "NCT05330325": {
    "nct_id": "NCT05330325",
    "brief_title": "A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow",
    "official_title": "A Study Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® as Well as Evaluating Long-term Safety of Somapacitan in a Basket Study Design in Children With Short Stature Either Born Small for Gestational Age or With Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Somapacitan"
      },
      {
        "type": "DRUG",
        "name": "Norditropin®"
      }
    ],
    "enrollment": 399,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-22"
  },
  "NCT05388708": {
    "nct_id": "NCT05388708",
    "brief_title": "ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)",
    "official_title": "ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "DEVICE",
        "name": "ECMO support"
      },
      {
        "type": "OTHER",
        "name": "PROSpect protocolized therapies"
      }
    ],
    "enrollment": 550,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-12-17"
  },
  "NCT06758492": {
    "nct_id": "NCT06758492",
    "brief_title": "A Prospective Observational Study of Video Laryngoscopy Versus Direct Laryngoscopy for Insertion of a Thin Endotracheal Catheter for Surfactant Administration in Newborn Infants",
    "official_title": "A Prospective Observational Study of Video Laryngoscopy Versus Direct Laryngoscopy for Insertion of a Thin Endotracheal Catheter for Surfactant Administration in Newborn Infants",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "DEVICE",
        "name": "Video laryngoscopy used to insert thin endotracheal catheter"
      },
      {
        "type": "DEVICE",
        "name": "Direct laryngoscopy used to insert thin endotracheal catheter"
      }
    ],
    "enrollment": 600,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-02-20"
  },
  "NCT06857604": {
    "nct_id": "NCT06857604",
    "brief_title": "The Interplay Between Inborn Error of Immunity and Blood Disorders: Unravelling Immune Defects Behind Common Haematological Diseases",
    "official_title": "The Interplay Between Inborn Error of Immunity and Blood Disorders: Unravelling Immune Defects Behind Common Haematological Diseases",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "OTHER",
        "name": "Biological samples"
      }
    ],
    "enrollment": 700,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-04"
  },
  "NCT05309668": {
    "nct_id": "NCT05309668",
    "brief_title": "Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN",
    "official_title": "A Phase I/II, Single-Arm, Open Label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With Neurofibromatosis Type 1 (NF1) Related Symptomatic, Inoperable Plexiform Neurofibromas (PN) (SPRINKLE)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Selumetinib granule formulation"
      },
      {
        "type": "DRUG",
        "name": "Selumetinib capsule formulation"
      }
    ],
    "enrollment": 36,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-14"
  },
  "NCT06757543": {
    "nct_id": "NCT06757543",
    "brief_title": "A Stepped Wedge Cluster Randomised Trial of Video Versus Direct Laryngoscopy for Intubation of Newborn Infants",
    "official_title": "A Stepped Wedge Cluster Randomised Trial of Video Versus Direct Laryngoscopy for Intubation of Newborn Infants",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "DEVICE",
        "name": "Video laryngoscopy"
      },
      {
        "type": "DEVICE",
        "name": "Direct laryngoscopy with standard laryngoscope"
      }
    ],
    "enrollment": 840,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-02-20"
  },
  "NCT05949684": {
    "nct_id": "NCT05949684",
    "brief_title": "ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions",
    "official_title": "A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The \"ELEMENT-MDS\" Trial",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "Luspatercept"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Epoetin Alfa"
      }
    ],
    "enrollment": 360,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-27"
  },
  "NCT06366464": {
    "nct_id": "NCT06366464",
    "brief_title": "A Study of Pitolisant in Patients With Prader-Willi Syndrome",
    "official_title": "A Phase 3, Randomized, Double-Blind, Placebo-controlled, Efficacy and Safety Study of Pitolisant Followed by an Open-Label Extension in Patients With Prader-Willi Syndrome",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Pitolisant tablet"
      },
      {
        "type": "OTHER",
        "name": "Placebo tablet"
      }
    ],
    "enrollment": 134,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-12"
  },
  "NCT06388564": {
    "nct_id": "NCT06388564",
    "brief_title": "A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease",
    "official_title": "A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Axatilimab"
      },
      {
        "type": "DRUG",
        "name": "Ruxolitinib"
      },
      {
        "type": "DRUG",
        "name": "Corticosteroids"
      }
    ],
    "enrollment": 120,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-27"
  },
  "NCT04963179": {
    "nct_id": "NCT04963179",
    "brief_title": "PREvention of Intrauterine Adhesion After Adhesiolysis With Novel Tri-block deGradable Polymer Film.",
    "official_title": "PREvention of Intrauterine Adhesion After Adhesiolysis With Novel Tri-block deGradable Polymer Film.",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "DEVICE",
        "name": "Womed Leaf"
      }
    ],
    "enrollment": 160,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-27"
  },
  "NCT02962414": {
    "nct_id": "NCT02962414",
    "brief_title": "Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment",
    "official_title": "An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "everolimus"
      }
    ],
    "enrollment": 206,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-28"
  },
  "NCT05405114": {
    "nct_id": "NCT05405114",
    "brief_title": "Research Study Investigating How Well NDec Works in People With Sickle Cell Disease",
    "official_title": "A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell Disease",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "NDec - oral decitabine-tetrahydrouridine"
      },
      {
        "type": "DRUG",
        "name": "HU - Hydroxyurea"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 84,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-25"
  },
  "NCT04337450": {
    "nct_id": "NCT04337450",
    "brief_title": "DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old",
    "official_title": "A Randomised Non-inferiority Trial With Nested PK to Assess DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Dolutegravir (DTG) and lamivudine (3TC)"
      },
      {
        "type": "DRUG",
        "name": "SOC"
      }
    ],
    "enrollment": 370,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-02"
  },
  "NCT05163314": {
    "nct_id": "NCT05163314",
    "brief_title": "A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome",
    "official_title": "A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Soticlestat"
      }
    ],
    "enrollment": 400,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-27"
  },
  "NCT06209346": {
    "nct_id": "NCT06209346",
    "brief_title": "Multimodal Physiotherapy Based on Tele-rehabilitation in Chronic Pelvic Pain Associated With Endometriosis",
    "official_title": "Multimodal Physiotherapy Based on Tele-rehabilitation in Chronic Pelvic Pain Associated With Endometriosis",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "OTHER",
        "name": "TeleRehab Group"
      },
      {
        "type": "OTHER",
        "name": "Advices Group"
      }
    ],
    "enrollment": 66,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-01-17"
  },
  "NCT06673069": {
    "nct_id": "NCT06673069",
    "brief_title": "Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)",
    "official_title": "A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION269 in Adults With Down Syndrome (Hero Study)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "ION269"
      }
    ],
    "enrollment": 30,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-01"
  },
  "NCT05453968": {
    "nct_id": "NCT05453968",
    "brief_title": "Berotralstat Treatment in Children With Hereditary Angioedema",
    "official_title": "A Phase 3 Study to Evaluate the Safety and Pharmacokinetics of Berotralstat Prophylaxis in Children With Hereditary Angioedema Who Are 2 to < 12 Years of Age",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Berotralstat"
      }
    ],
    "enrollment": 29,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-10-15"
  },
  "NCT05200715": {
    "nct_id": "NCT05200715",
    "brief_title": "AutoInflammatory Disease Alliance Registry (AIDA)",
    "official_title": "Development of an International Multicenter Registry of Patients With Monogenic and Polygenic Autoinflammatory Diseases Aimed at Clinical and Therapeutical Data Collection and Analysis",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "OTHER",
        "name": "No intervention is foreseen by the protocol."
      }
    ],
    "enrollment": 3500,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-29"
  },
  "NCT06115109": {
    "nct_id": "NCT06115109",
    "brief_title": "Angelman Natural History Study - FAST Spain",
    "official_title": "Observational Study, Prospective Multicentric, From the Natural History of Patients With Angelman Syndrome in Spain",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "OTHER",
        "name": "Non intervention, Observational study"
      }
    ],
    "enrollment": 40,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-04-03"
  },
  "NCT06392009": {
    "nct_id": "NCT06392009",
    "brief_title": "Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II",
    "official_title": "A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodil in Patients With Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type II",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Radiprodil"
      }
    ],
    "enrollment": 30,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-03"
  },
  "NCT06183788": {
    "nct_id": "NCT06183788",
    "brief_title": "Antibody-mediated NMDA Receptor Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Prolonged Recovery Stage",
    "official_title": "Antibody-mediated NMDA Receptor Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Prolonged Recovery Stage",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "BEHAVIORAL",
        "name": "Remote cognitive rehabilitation program"
      }
    ],
    "enrollment": 20,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-05-06"
  },
  "NCT05572515": {
    "nct_id": "NCT05572515",
    "brief_title": "A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma",
    "official_title": "A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Teclistamab"
      },
      {
        "type": "DRUG",
        "name": "Pomalidomide"
      },
      {
        "type": "DRUG",
        "name": "Bortezomib"
      },
      {
        "type": "DRUG",
        "name": "Dexamethasone"
      },
      {
        "type": "DRUG",
        "name": "Carfilzomib"
      }
    ],
    "enrollment": 650,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-23"
  },
  "NCT03717909": {
    "nct_id": "NCT03717909",
    "brief_title": "Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome",
    "official_title": "A Pivotal, International, Randomised, Double-blind, Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Sodium Valproate 200Mg E/C Tablet"
      },
      {
        "type": "DRUG",
        "name": "Sodium Valproate matched placebo"
      }
    ],
    "enrollment": 63,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-07-31"
  },
  "NCT05388370": {
    "nct_id": "NCT05388370",
    "brief_title": "PASS of Paediatric Patients Initiating Selumetinib",
    "official_title": "Post-Authorisation Safety Study of Paediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort Study.",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 125,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-03"
  },
  "NCT06668805": {
    "nct_id": "NCT06668805",
    "brief_title": "A Phase 2 Basket Study of Vosoritide in Children With Turner Syndrome, SHOX Deficiency and Noonan Syndrome With an Inadequate Response to Human Growth Hormone",
    "official_title": "A Phase 2, Randomized, Human Growth Hormone-Controlled, Multicenter, Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With an Inadequate Response to Human Growth Hormone. (CANOPY NS, TS, SHOX-D-2)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Vosoritide Injection"
      },
      {
        "type": "DRUG",
        "name": "Human Growth Hormone"
      }
    ],
    "enrollment": 72,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-13"
  },
  "NCT06305611": {
    "nct_id": "NCT06305611",
    "brief_title": "European and North Indian Cohort of KaWasaki dIsease",
    "official_title": "Comparison and Performance of Kobayashi and Kawanet IVIg Resistance Scores in a Multi-centric European and North Indian Cohort of KaWasaki dIsease (the KIWI Study)",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 103,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-03-12"
  },
  "NCT05219617": {
    "nct_id": "NCT05219617",
    "brief_title": "Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults",
    "official_title": "A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults, With Optional Open-Label Extension",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Carisbamate"
      }
    ],
    "enrollment": 252,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      },
      {
        "orpha_code": "709",
        "disease_name": "Peters plus syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-24"
  },
  "NCT05912517": {
    "nct_id": "NCT05912517",
    "brief_title": "A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)",
    "official_title": "A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Nipocalimab"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 120,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-22"
  },
  "NCT06052436": {
    "nct_id": "NCT06052436",
    "brief_title": "Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2)",
    "official_title": "Open Phase I/IIa Clinical Trial to Evaluate the Safety and Efficacy of Allogenic Administration of Treg Cells Obtained From Thymic Tissue (thyTreg) to Control The Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "Allogeneic thyTreg 5.000.000"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Allogeneic thyTreg 10.000.000"
      }
    ],
    "enrollment": 24,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-02-03"
  },
  "NCT05020236": {
    "nct_id": "NCT05020236",
    "brief_title": "A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments",
    "official_title": "AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Elranatamab"
      },
      {
        "type": "DRUG",
        "name": "Daratumumab"
      },
      {
        "type": "DRUG",
        "name": "Pomalidomide"
      },
      {
        "type": "DRUG",
        "name": "Dexamethasone"
      }
    ],
    "enrollment": 944,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-02"
  },
  "NCT05468736": {
    "nct_id": "NCT05468736",
    "brief_title": "Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years",
    "official_title": "A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)"
      },
      {
        "type": "OTHER",
        "name": "Placebo"
      }
    ],
    "enrollment": 3600,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-12-20"
  },
  "NCT04462770": {
    "nct_id": "NCT04462770",
    "brief_title": "A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome",
    "official_title": "A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Clemizole HCl"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 150,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      },
      {
        "orpha_code": "709",
        "disease_name": "Peters plus syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-16"
  },
  "NCT03227042": {
    "nct_id": "NCT03227042",
    "brief_title": "A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)",
    "official_title": "A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 44,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      },
      {
        "orpha_code": "581",
        "disease_name": "Mucopolysaccharidosis type 3"
      }
    ],
    "locations_spain": true,
    "last_update": "2022-10-26"
  },
  "NCT06193200": {
    "nct_id": "NCT06193200",
    "brief_title": "Evaluate the Neurological Effects of EryDex on Subjects With A-T",
    "official_title": "A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on Subjects With Ataxia Telangiectasia (NEAT)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Dexamethasone sodium phosphate"
      },
      {
        "type": "OTHER",
        "name": "Placebo"
      }
    ],
    "enrollment": 106,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-29"
  },
  "NCT04649359": {
    "nct_id": "NCT04649359",
    "brief_title": "MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb",
    "official_title": "MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Elranatamab (PF-06863135)"
      }
    ],
    "enrollment": 187,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-01-27"
  },
  "NCT04924075": {
    "nct_id": "NCT04924075",
    "brief_title": "Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)",
    "official_title": "A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Belzutifan"
      }
    ],
    "enrollment": 322,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-29"
  },
  "NCT04015141": {
    "nct_id": "NCT04015141",
    "brief_title": "A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy",
    "official_title": "An Open-Label Study With Extension Phase to Evaluate the Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to Less Than 18 Years) With Childhood Epilepsy",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Perampanel Oral Suspension"
      },
      {
        "type": "DRUG",
        "name": "Perampanel Tablet"
      }
    ],
    "enrollment": 100,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-22"
  },
  "NCT06515106": {
    "nct_id": "NCT06515106",
    "brief_title": "Antibody-mediated LGI1 Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Chronic Phase of the Disease",
    "official_title": "Antibody-mediated LGI1 Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Chronic Phase of the Disease",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "BEHAVIORAL",
        "name": "Remote cognitive rehabilitation program"
      }
    ],
    "enrollment": 20,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      },
      {
        "orpha_code": "588",
        "disease_name": "Muscle-eye-brain disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-07-23"
  },
  "NCT06719141": {
    "nct_id": "NCT06719141",
    "brief_title": "A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)",
    "official_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults With Developmental and Epileptic Encephalopathies",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "LP352"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 320,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-13"
  },
  "NCT06317883": {
    "nct_id": "NCT06317883",
    "brief_title": "Childhood Obesity Risk Assessment Longitudinal Study",
    "official_title": "Longitudinal Study To Determine The Risk Factors Associated With Childhood Obesity",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 1508,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-05-30"
  },
  "NCT03089905": {
    "nct_id": "NCT03089905",
    "brief_title": "A Study to Compare the Long-term Outcomes After Two Different Anaesthetics",
    "official_title": "Neurodevelopmental Outcome After Standard Dose Sevoflurane Versus Low-dose Sevoflurane/Dexmedetomidine/Remifentanil Anaesthesia in Young Children- The TREX Trial",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Sevoflurane"
      },
      {
        "type": "DRUG",
        "name": "Remifentanil"
      },
      {
        "type": "DRUG",
        "name": "Dexmedetomidine"
      }
    ],
    "enrollment": 450,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-07-05"
  },
  "NCT05319353": {
    "nct_id": "NCT05319353",
    "brief_title": "A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)",
    "official_title": "A Phase 3, Open-label, Single-arm, Repeated-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Maribavir"
      }
    ],
    "enrollment": 80,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-12-10"
  },
  "NCT06125093": {
    "nct_id": "NCT06125093",
    "brief_title": "Study of an Early Parenting Intervention for Children With Genetic Abnormalities and Mental Health Problems",
    "official_title": "Early Treatment for Children With Mental Health Problems and Genetic Abnormalities Through a Parenting Intervention (The GAP): A Pragmatic Randomized Controlled Trial",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "BEHAVIORAL",
        "name": "Incredible Years Autism Spectrum and Language Delays Parent Program (IY-ASLD®)"
      }
    ],
    "enrollment": 68,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2023-11-09"
  },
  "NCT06694805": {
    "nct_id": "NCT06694805",
    "brief_title": "A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1",
    "official_title": "A Phase 3b, Open Label, Randomized, standard-of Care Control Arm, Multicenter, Superiority Study Evaluating the Efficacy, Safety, and Tolerability of Injectable CAB LA + RPV LA in Viremic Participants Living With HIV-1 (CROWN)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "CAB LA + RPV LA"
      },
      {
        "type": "DRUG",
        "name": "Oral ART"
      }
    ],
    "enrollment": 332,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-17"
  },
  "NCT05639647": {
    "nct_id": "NCT05639647",
    "brief_title": "Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections",
    "official_title": "A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTION",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "ATM-AVI"
      },
      {
        "type": "DRUG",
        "name": "BAT"
      }
    ],
    "enrollment": 48,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-06"
  },
  "NCT05767047": {
    "nct_id": "NCT05767047",
    "brief_title": "A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis",
    "official_title": "A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet's Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Apremilast"
      }
    ],
    "enrollment": 48,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-24"
  },
  "NCT02621645": {
    "nct_id": "NCT02621645",
    "brief_title": "TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence",
    "official_title": "Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence: an Open-label Randomized Controlled Trial: TRAPIST - TRAP Intervention STudy",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      {
        "type": "PROCEDURE",
        "name": "Early selective reduction of TRAP mass"
      },
      {
        "type": "PROCEDURE",
        "name": "Late selective reduction of TRAP mass"
      },
      {
        "type": "DEVICE",
        "name": "Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle"
      },
      {
        "type": "DEVICE",
        "name": "Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle"
      },
      {
        "type": "DEVICE",
        "name": "Laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber"
      }
    ],
    "enrollment": 126,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-07-10"
  },
  "NCT03339128": {
    "nct_id": "NCT03339128",
    "brief_title": "Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children",
    "official_title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Participants (Age 6 to 17 Years) With Irritable Bowel Syndrome With Diarrhea (IBS-D)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Eluxadoline"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 95,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-05"
  },
  "NCT06664853": {
    "nct_id": "NCT06664853",
    "brief_title": "Open-Label Extension of EryDex Study IEDAT-04-2022",
    "official_title": "An Open-Label Extension Study of EryDex in Patients With Ataxia Telangiectasia Following Participation in Study IEDAT-04-2022 (NEAT)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Dexamethasone sodium phosphate"
      }
    ],
    "enrollment": 106,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-01"
  },
  "NCT04777851": {
    "nct_id": "NCT04777851",
    "brief_title": "Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7",
    "official_title": "A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate the Safety and Efficacy of Systemic Therapy With Regorafenib and Pembrolizumab Versus Locoregional Therapy With Transarterial Chemoembolization or Transarterial Radioembolization, for the First-line Treatment of Intermediate-stage Hepatocellular Carcinoma With Beyond Up-to-7 Criteria",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Regorafenib in combination with pembrolizumab"
      },
      {
        "type": "PROCEDURE",
        "name": "Loco-regional therapy"
      }
    ],
    "enrollment": 496,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-15"
  },
  "NCT04069533": {
    "nct_id": "NCT04069533",
    "brief_title": "Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A",
    "official_title": "A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients With Fanconi Anemia Subtype A",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "RP-L102"
      }
    ],
    "enrollment": 7,
    "diseases": [
      {
        "orpha_code": "139",
        "disease_name": "CHILD syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-05-22"
  },
  "NCT05933200": {
    "nct_id": "NCT05933200",
    "brief_title": "A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD",
    "official_title": "A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared With Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Triheptanoin"
      },
      {
        "type": "DIETARY_SUPPLEMENT",
        "name": "MCT Oil"
      }
    ],
    "enrollment": 60,
    "diseases": [
      {
        "orpha_code": "156",
        "disease_name": "Carnitine palmitoyl transferase 1A deficiency"
      },
      {
        "orpha_code": "157",
        "disease_name": "Carnitine palmitoyltransferase II deficiency"
      },
      {
        "orpha_code": "159",
        "disease_name": "Carnitine-acylcarnitine translocase deficiency"
      },
      {
        "orpha_code": "26793",
        "disease_name": "Very long chain acyl-CoA dehydrogenase deficiency"
      },
      {
        "orpha_code": "42",
        "disease_name": "Medium chain acyl-CoA dehydrogenase deficiency"
      },
      {
        "orpha_code": "5",
        "disease_name": "Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency"
      },
      {
        "orpha_code": "746",
        "disease_name": "Mitochondrial trifunctional protein deficiency"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-12"
  },
  "NCT03659916": {
    "nct_id": "NCT03659916",
    "brief_title": "Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC",
    "official_title": "An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "A4250 (odevixibat)"
      }
    ],
    "enrollment": 116,
    "diseases": [
      {
        "orpha_code": "172",
        "disease_name": "Progressive familial intrahepatic cholestasis"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-10-31"
  },
  "NCT03758521": {
    "nct_id": "NCT03758521",
    "brief_title": "Natural History Study of Patients with Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency",
    "official_title": "Natural History Study of Patients with Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "DEVICE",
        "name": "Transcranial magnetic stimulation (TMS)"
      },
      {
        "type": "DEVICE",
        "name": "Magnetic resonance imaging (MRI)"
      },
      {
        "type": "DEVICE",
        "name": "Electroencephalogram (EEG)"
      },
      {
        "type": "PROCEDURE",
        "name": "Bio-specimen Collection"
      }
    ],
    "enrollment": 55,
    "diseases": [
      {
        "orpha_code": "22",
        "disease_name": "Succinic semialdehyde dehydrogenase deficiency"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-12-16"
  },
  "NCT06767605": {
    "nct_id": "NCT06767605",
    "brief_title": "Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai)",
    "official_title": "Registro Español de Enfermedades Hepáticas Colestásicas y Autoinmunes (ColHai)",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 5000,
    "diseases": [
      {
        "orpha_code": "234",
        "disease_name": "Dubin-Johnson syndrome"
      },
      {
        "orpha_code": "3111",
        "disease_name": "Rotor syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-01-10"
  },
  "NCT02938520": {
    "nct_id": "NCT02938520",
    "brief_title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants",
    "official_title": "A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Cabotegravir (CAB) tablet"
      },
      {
        "type": "DRUG",
        "name": "Rilpivirine (RPV) tablet"
      },
      {
        "type": "DRUG",
        "name": "Cabotegravir - Injectable Suspension (CAB LA)"
      },
      {
        "type": "DRUG",
        "name": "Rilpivirine - Injectable Suspension (RPV LA)"
      },
      {
        "type": "DRUG",
        "name": "ABC/DTG/3TC STR - Tablet"
      },
      {
        "type": "DRUG",
        "name": "DTG Tablet"
      }
    ],
    "enrollment": 631,
    "diseases": [
      {
        "orpha_code": "251383",
        "disease_name": "CK syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-21"
  },
  "NCT05027984": {
    "nct_id": "NCT05027984",
    "brief_title": "Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS",
    "official_title": "An Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria Identified by Optical Coherence Tomography in Patients With Acute Coronary Syndrome (the INTER-CLIMA Trial)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "DEVICE",
        "name": "Optical coherence tomography"
      },
      {
        "type": "DEVICE",
        "name": "iFR/FFR/RFR"
      }
    ],
    "enrollment": 1420,
    "diseases": [
      {
        "orpha_code": "251383",
        "disease_name": "CK syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-26"
  },
  "NCT06684379": {
    "nct_id": "NCT06684379",
    "brief_title": "Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Prevention of COVID-19-Associated Cytokine Storm",
    "official_title": "Double-blind, Randomized, Placebo-controlled, Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Two Doses of a Conditioned Medium From a Co-culture of M2-macrophages and Mesenchymal Cells (PRS CK STORM) in the Prevention of COVID-19-associated Cytokine Storm (PRSMA)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Placebo comparator"
      },
      {
        "type": "DRUG",
        "name": "PRS CK STORM"
      },
      {
        "type": "DRUG",
        "name": "PRS CK STORM"
      }
    ],
    "enrollment": 50,
    "diseases": [
      {
        "orpha_code": "251383",
        "disease_name": "CK syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-11-14"
  },
  "NCT02951052": {
    "nct_id": "NCT02951052",
    "brief_title": "Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults",
    "official_title": "A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current INI- NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Cabotegravir (CAB) tablet"
      },
      {
        "type": "DRUG",
        "name": "Rilpivirine (RPV) tablet"
      },
      {
        "type": "DRUG",
        "name": "Cabotegravir - Injectable Suspension (CAB LA)"
      },
      {
        "type": "DRUG",
        "name": "Rilpivirine - Injectable Suspension (RPV LA)"
      },
      {
        "type": "DRUG",
        "name": "2 NRTIs plus an INI, NNRTI, or PI"
      }
    ],
    "enrollment": 618,
    "diseases": [
      {
        "orpha_code": "251383",
        "disease_name": "CK syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-01-22"
  },
  "NCT05650229": {
    "nct_id": "NCT05650229",
    "brief_title": "Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease",
    "official_title": "An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Adaptive Study of the Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "KL1333"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 180,
    "diseases": [
      {
        "orpha_code": "2596",
        "disease_name": "Myopathy and diabetes mellitus"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-22"
  },
  "NCT01633489": {
    "nct_id": "NCT01633489",
    "brief_title": "Lysosomal Acid Lipase (LAL) Deficiency Registry",
    "official_title": "An Observational Disease and Clinical Outcomes Registry of Patients With Lysosomal Acid Lipase (LAL) Deficiency",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 300,
    "diseases": [
      {
        "orpha_code": "275761",
        "disease_name": "Lysosomal acid lipase deficiency"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-25"
  },
  "NCT05658822": {
    "nct_id": "NCT05658822",
    "brief_title": "Digestive Dysmotility in Mitochondrial Neurogastrointestinal Encephalomyopathy",
    "official_title": "Enteric Dysmotility in Mitochondrial Neurogastrointestinal Encephalomyopathy Patients Detected by High-resolution",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 6,
    "diseases": [
      {
        "orpha_code": "298",
        "disease_name": "Mitochondrial neurogastrointestinal encephalomyopathy"
      }
    ],
    "locations_spain": true,
    "last_update": "2022-12-21"
  },
  "NCT04408625": {
    "nct_id": "NCT04408625",
    "brief_title": "Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)",
    "official_title": "A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients With Fronto-Temporal Dementia With Progranulin Mutations (FTD-GRN)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "LY3884963"
      },
      {
        "type": "DRUG",
        "name": "Methylprednisolone"
      },
      {
        "type": "DRUG",
        "name": "Optional Sirolimus"
      },
      {
        "type": "DRUG",
        "name": "Optional Prednisone"
      }
    ],
    "enrollment": 30,
    "diseases": [
      {
        "orpha_code": "314629",
        "disease_name": "CLN11 disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-18"
  },
  "NCT06064890": {
    "nct_id": "NCT06064890",
    "brief_title": "A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)",
    "official_title": "A Phase 1/2 Open-Label, Ascending Dose, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "PROCEDURE",
        "name": "Intrathalamic AAV.PGRN administration"
      },
      {
        "type": "GENETIC",
        "name": "Intrathalamic AVB-101"
      }
    ],
    "enrollment": 9,
    "diseases": [
      {
        "orpha_code": "314629",
        "disease_name": "CLN11 disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-22"
  },
  "NCT04374136": {
    "nct_id": "NCT04374136",
    "brief_title": "A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)",
    "official_title": "A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "AL001"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      },
      {
        "type": "DRUG",
        "name": "Open label - AL001"
      }
    ],
    "enrollment": 110,
    "diseases": [
      {
        "orpha_code": "314629",
        "disease_name": "CLN11 disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-08"
  },
  "NCT05280548": {
    "nct_id": "NCT05280548",
    "brief_title": "A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease",
    "official_title": "A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Venglustat (GZ402671)"
      },
      {
        "type": "DRUG",
        "name": "Agalsidase alfa"
      },
      {
        "type": "DRUG",
        "name": "Agalsidase beta (GZ419828)"
      },
      {
        "type": "DRUG",
        "name": "Migalastat"
      }
    ],
    "enrollment": 104,
    "diseases": [
      {
        "orpha_code": "324",
        "disease_name": "Fabry disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-01-13"
  },
  "NCT04020055": {
    "nct_id": "NCT04020055",
    "brief_title": "A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease",
    "official_title": "An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects With Fabry Disease and Amenable GLA Variants and Severe Renal Impairment or End-Stage Renal Disease Treated With Hemodialysis",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "migalastat HCl 150 mg"
      }
    ],
    "enrollment": 14,
    "diseases": [
      {
        "orpha_code": "324",
        "disease_name": "Fabry disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-03"
  },
  "NCT03737214": {
    "nct_id": "NCT03737214",
    "brief_title": "A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease",
    "official_title": "A Multi-center, Open-label, Uncontrolled, Single-arm, Extension Study to Determine the Long-term Safety and Tolerability of Oral Lucerastat in Adult Subjects With Fabry Disease",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Lucerastat"
      }
    ],
    "enrollment": 107,
    "diseases": [
      {
        "orpha_code": "324",
        "disease_name": "Fabry disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-25"
  },
  "NCT06328608": {
    "nct_id": "NCT06328608",
    "brief_title": "A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease",
    "official_title": "Multi-centre, Open-label Trial to Assess the saFety, Pharmacodynamics, Efficacy and Pharmacokinetics of pegunigaLsidase Alfa in Patients From 2 Years to Less Than 18 Years of Age With Confirmed FabrY Disease",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "PRX-102 1 mg/kg every two weeks"
      }
    ],
    "enrollment": 22,
    "diseases": [
      {
        "orpha_code": "324",
        "disease_name": "Fabry disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-12-20"
  },
  "NCT00196742": {
    "nct_id": "NCT00196742",
    "brief_title": "Fabry Disease Registry & Pregnancy Sub-registry",
    "official_title": "Fabry Disease Registry Protocol",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 9000,
    "diseases": [
      {
        "orpha_code": "324",
        "disease_name": "Fabry disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-11-20"
  },
  "NCT02988128": {
    "nct_id": "NCT02988128",
    "brief_title": "Neurovascular Product Surveillance Registry",
    "official_title": "NeuroVascular Product Surveillance Registry (PSR) Platform",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "DEVICE",
        "name": "Treatment for intracranial aneurysms"
      },
      {
        "type": "DEVICE",
        "name": "Treatment for Acute Ischemic Stroke"
      }
    ],
    "enrollment": 4000,
    "diseases": [
      {
        "orpha_code": "324",
        "disease_name": "Fabry disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-02"
  },
  "NCT01804686": {
    "nct_id": "NCT01804686",
    "brief_title": "A Long-term Extension Study of PCI-32765 (Ibrutinib)",
    "official_title": "A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Ibrutinib"
      }
    ],
    "enrollment": 700,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-23"
  },
  "NCT04245839": {
    "nct_id": "NCT04245839",
    "brief_title": "A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)",
    "official_title": "A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Fludarabine"
      },
      {
        "type": "DRUG",
        "name": "Cyclophosphamide"
      },
      {
        "type": "DRUG",
        "name": "JCAR017"
      }
    ],
    "enrollment": 276,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-19"
  },
  "NCT06479135": {
    "nct_id": "NCT06479135",
    "brief_title": "Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib",
    "official_title": "A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Navtemadlin"
      },
      {
        "type": "DRUG",
        "name": "Navtemadlin placebo"
      },
      {
        "type": "DRUG",
        "name": "Ruxolitinib"
      }
    ],
    "enrollment": 600,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-12-24"
  },
  "NCT01844986": {
    "nct_id": "NCT01844986",
    "brief_title": "Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.",
    "official_title": "A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Olaparib 300mg tablets"
      }
    ],
    "enrollment": 450,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-31"
  },
  "NCT05382286": {
    "nct_id": "NCT05382286",
    "brief_title": "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer",
    "official_title": "A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Sacituzumab Govitecan-hziy"
      },
      {
        "type": "DRUG",
        "name": "Pembrolizumab"
      },
      {
        "type": "DRUG",
        "name": "Paclitaxel"
      },
      {
        "type": "DRUG",
        "name": "nab-Paclitaxel"
      },
      {
        "type": "DRUG",
        "name": "Gemcitabine"
      },
      {
        "type": "DRUG",
        "name": "Carboplatin"
      }
    ],
    "enrollment": 443,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-12-24"
  },
  "NCT06090539": {
    "nct_id": "NCT06090539",
    "brief_title": "A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas",
    "official_title": "A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "BMS-986458"
      },
      {
        "type": "DRUG",
        "name": "Rituximab"
      }
    ],
    "enrollment": 273,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-09-20"
  },
  "NCT05153239": {
    "nct_id": "NCT05153239",
    "brief_title": "Clinical Trial of Lurbinectedin As Single-agent or in Combination with Irinotecan Versus Topotecan or Irinotecan in Patients with Relapsed Small-cell Lung Cancer (LAGOON)",
    "official_title": "A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Irinotecan"
      },
      {
        "type": "DRUG",
        "name": "Lurbinectedin"
      },
      {
        "type": "DRUG",
        "name": "Irinotecan"
      },
      {
        "type": "DRUG",
        "name": "Topotecan"
      },
      {
        "type": "DRUG",
        "name": "Lurbinectedin"
      }
    ],
    "enrollment": 705,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-01-30"
  },
  "NCT05768139": {
    "nct_id": "NCT05768139",
    "brief_title": "First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors",
    "official_title": "First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "STX-478"
      },
      {
        "type": "DRUG",
        "name": "Fulvestrant"
      },
      {
        "type": "DRUG",
        "name": "Ribociclib"
      },
      {
        "type": "DRUG",
        "name": "Palbociclib"
      },
      {
        "type": "DRUG",
        "name": "Letrozole"
      },
      {
        "type": "DRUG",
        "name": "Anastrozole"
      },
      {
        "type": "DRUG",
        "name": "Exemestane"
      }
    ],
    "enrollment": 720,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-30"
  },
  "NCT06140524": {
    "nct_id": "NCT06140524",
    "brief_title": "A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma",
    "official_title": "Phase 2 Dose-Ranging and Interception Study of Linvoseltamab in Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Linvoseltamab"
      }
    ],
    "enrollment": 104,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-08"
  },
  "NCT05006716": {
    "nct_id": "NCT05006716",
    "brief_title": "A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies",
    "official_title": "A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "BGB-16673"
      }
    ],
    "enrollment": 621,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-24"
  },
  "NCT04077463": {
    "nct_id": "NCT04077463",
    "brief_title": "A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer",
    "official_title": "An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Lazertinib"
      },
      {
        "type": "DRUG",
        "name": "Amivantamab"
      },
      {
        "type": "DRUG",
        "name": "Carboplatin"
      },
      {
        "type": "DRUG",
        "name": "Pemetrexed"
      }
    ],
    "enrollment": 701,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-22"
  },
  "NCT04626635": {
    "nct_id": "NCT04626635",
    "brief_title": "A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers",
    "official_title": "A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "REGN7075"
      },
      {
        "type": "DRUG",
        "name": "Cemiplimab"
      },
      {
        "type": "DRUG",
        "name": "Platinum-based doublet chemotherapy"
      },
      {
        "type": "DRUG",
        "name": "Bevacizumab"
      },
      {
        "type": "DRUG",
        "name": "Trifluridine-tipiracil"
      }
    ],
    "enrollment": 933,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-25"
  },
  "NCT05183035": {
    "nct_id": "NCT05183035",
    "brief_title": "Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)",
    "official_title": "A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Fludarabine"
      },
      {
        "type": "DRUG",
        "name": "Cytarabine"
      },
      {
        "type": "DRUG",
        "name": "Gemtuzumab Ozogamicin"
      },
      {
        "type": "DRUG",
        "name": "Azacitidine"
      },
      {
        "type": "DRUG",
        "name": "Venetoclax"
      }
    ],
    "enrollment": 98,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-01-16"
  },
  "NCT03142334": {
    "nct_id": "NCT03142334",
    "brief_title": "Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)",
    "official_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "Pembrolizumab"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 994,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-11-13"
  },
  "NCT03093116": {
    "nct_id": "NCT03093116",
    "brief_title": "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",
    "official_title": "A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Oral repotrectinib (TPX-0005)"
      }
    ],
    "enrollment": 500,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-06"
  },
  "NCT02716116": {
    "nct_id": "NCT02716116",
    "brief_title": "A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer",
    "official_title": "A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "TAK-788"
      }
    ],
    "enrollment": 334,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-06"
  },
  "NCT05836324": {
    "nct_id": "NCT05836324",
    "brief_title": "A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors",
    "official_title": "A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "INCA33890"
      },
      {
        "type": "DRUG",
        "name": "bevacizumab"
      },
      {
        "type": "DRUG",
        "name": "FOLFIRI"
      },
      {
        "type": "DRUG",
        "name": "FOLFOX"
      },
      {
        "type": "DRUG",
        "name": "Cetuximab"
      }
    ],
    "enrollment": 408,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-01"
  },
  "NCT03175224": {
    "nct_id": "NCT03175224",
    "brief_title": "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors",
    "official_title": "Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "APL-101 Oral Capsules"
      }
    ],
    "enrollment": 497,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-27"
  },
  "NCT06625320": {
    "nct_id": "NCT06625320",
    "brief_title": "Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)",
    "official_title": "RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "RMC-6236"
      },
      {
        "type": "DRUG",
        "name": "Gemcitabine"
      },
      {
        "type": "DRUG",
        "name": "nab-paclitaxel"
      },
      {
        "type": "DRUG",
        "name": "Irinotecan"
      },
      {
        "type": "DRUG",
        "name": "Liposomal irinotecan"
      },
      {
        "type": "DRUG",
        "name": "5-fluorouracil"
      },
      {
        "type": "DRUG",
        "name": "leucovorin"
      },
      {
        "type": "DRUG",
        "name": "Oxaliplatin"
      }
    ],
    "enrollment": 460,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-21"
  },
  "NCT04449874": {
    "nct_id": "NCT04449874",
    "brief_title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",
    "official_title": "A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "GDC-6036"
      },
      {
        "type": "DRUG",
        "name": "Atezolizumab"
      },
      {
        "type": "DRUG",
        "name": "Cetuximab"
      },
      {
        "type": "DRUG",
        "name": "Bevacizumab"
      },
      {
        "type": "DRUG",
        "name": "Erlotinib"
      },
      {
        "type": "DRUG",
        "name": "GDC-1971"
      },
      {
        "type": "DRUG",
        "name": "Inavolisib"
      }
    ],
    "enrollment": 498,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-08"
  },
  "NCT03394365": {
    "nct_id": "NCT03394365",
    "brief_title": "Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy",
    "official_title": "Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "tabelecleucel"
      }
    ],
    "enrollment": 66,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-02"
  },
  "NCT04601857": {
    "nct_id": "NCT04601857",
    "brief_title": "Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma",
    "official_title": "A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "futibatinib and pembrolizumab (KEYTRUDA®))"
      }
    ],
    "enrollment": 43,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-04"
  },
  "NCT04590326": {
    "nct_id": "NCT04590326",
    "brief_title": "A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018",
    "official_title": "Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "REGN5668"
      },
      {
        "type": "DRUG",
        "name": "Cemiplimab"
      },
      {
        "type": "DRUG",
        "name": "REGN4018"
      },
      {
        "type": "DRUG",
        "name": "Sarilumab"
      }
    ],
    "enrollment": 612,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-10"
  },
  "NCT05384626": {
    "nct_id": "NCT05384626",
    "brief_title": "A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)",
    "official_title": "A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "NVL-655"
      }
    ],
    "enrollment": 470,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-12-13"
  },
  "NCT04720157": {
    "nct_id": "NCT04720157",
    "brief_title": "An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC",
    "official_title": "An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "177Lu-PSMA-617"
      },
      {
        "type": "DRUG",
        "name": "68Ga-PSMA-11"
      },
      {
        "type": "DRUG",
        "name": "ARDT"
      },
      {
        "type": "DRUG",
        "name": "ADT"
      }
    ],
    "enrollment": 1145,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-11"
  },
  "NCT05592626": {
    "nct_id": "NCT05592626",
    "brief_title": "A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors",
    "official_title": "A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "STAR0602"
      }
    ],
    "enrollment": 365,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-01-30"
  },
  "NCT05718557": {
    "nct_id": "NCT05718557",
    "brief_title": "Study of PYX-106 in Solid Tumors",
    "official_title": "A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects With Advanced Solid Tumors",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "PYX-106"
      }
    ],
    "enrollment": 47,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-01"
  },
  "NCT04401748": {
    "nct_id": "NCT04401748",
    "brief_title": "Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome",
    "official_title": "A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Venetoclax"
      },
      {
        "type": "DRUG",
        "name": "Azacitidine"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 531,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-06-20"
  },
  "NCT06065748": {
    "nct_id": "NCT06065748",
    "brief_title": "A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)",
    "official_title": "A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Giredestrant"
      },
      {
        "type": "DRUG",
        "name": "Fulvestrant"
      },
      {
        "type": "DRUG",
        "name": "Abemaciclib"
      },
      {
        "type": "DRUG",
        "name": "Palbociclib"
      },
      {
        "type": "DRUG",
        "name": "Ribociclib"
      },
      {
        "type": "DRUG",
        "name": "LHRH Agonist"
      },
      {
        "type": "DIAGNOSTIC_TEST",
        "name": "FoundationOne Liquid CDx Assay (F1LCDx)"
      }
    ],
    "enrollment": 1050,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-29"
  },
  "NCT03844048": {
    "nct_id": "NCT03844048",
    "brief_title": "An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial",
    "official_title": "An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Venetoclax"
      }
    ],
    "enrollment": 165,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-19"
  },
  "NCT05696626": {
    "nct_id": "NCT05696626",
    "brief_title": "Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation",
    "official_title": "An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Lasofoxifene in combination with abemaciclib"
      },
      {
        "type": "DRUG",
        "name": "Fulvestrant in combination with abemaciclib"
      }
    ],
    "enrollment": 500,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-03"
  },
  "NCT06396065": {
    "nct_id": "NCT06396065",
    "brief_title": "Phase III Study of AK112 for NSCLC Patients",
    "official_title": "A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "AK112 Injection"
      },
      {
        "type": "DRUG",
        "name": "Placebo Injection"
      }
    ],
    "enrollment": 420,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-10-08"
  },
  "NCT03662126": {
    "nct_id": "NCT03662126",
    "brief_title": "KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment",
    "official_title": "A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "KRT-232"
      },
      {
        "type": "DRUG",
        "name": "Best Available Therapy (BAT)"
      }
    ],
    "enrollment": 385,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2023-04-28"
  },
  "NCT04404660": {
    "nct_id": "NCT04404660",
    "brief_title": "A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)",
    "official_title": "An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "AUTO1"
      }
    ],
    "enrollment": 153,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-09-03"
  },
  "NCT04710576": {
    "nct_id": "NCT04710576",
    "brief_title": "A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)",
    "official_title": "AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Axatilimab"
      }
    ],
    "enrollment": 241,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-01-20"
  },
  "NCT04811560": {
    "nct_id": "NCT04811560",
    "brief_title": "A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia",
    "official_title": "A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Bleximenib"
      }
    ],
    "enrollment": 400,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-22"
  },
  "NCT05224141": {
    "nct_id": "NCT05224141",
    "brief_title": "Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)",
    "official_title": "A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "Pembrolizumab/Vibostolimab Co-Formulation"
      },
      {
        "type": "DRUG",
        "name": "Saline placebo"
      },
      {
        "type": "DRUG",
        "name": "Etoposide"
      },
      {
        "type": "DRUG",
        "name": "Cisplatin"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Atezolizumab"
      },
      {
        "type": "DRUG",
        "name": "Carboplatin"
      }
    ],
    "enrollment": 460,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-30"
  },
  "NCT05993299": {
    "nct_id": "NCT05993299",
    "brief_title": "Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma",
    "official_title": "Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Letetresgene autoleucel"
      },
      {
        "type": "DRUG",
        "name": "Cyclophosphamide"
      },
      {
        "type": "DRUG",
        "name": "Fludarabine"
      }
    ],
    "enrollment": 7,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      },
      {
        "orpha_code": "699",
        "disease_name": "Pearson syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-10-22"
  },
  "NCT05218499": {
    "nct_id": "NCT05218499",
    "brief_title": "Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma",
    "official_title": "Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of Brigimadlin (BI 907828) Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Brigimadlin (BI 907828)"
      },
      {
        "type": "DRUG",
        "name": "Doxorubicin"
      }
    ],
    "enrollment": 401,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-24"
  },
  "NCT02912949": {
    "nct_id": "NCT02912949",
    "brief_title": "A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)",
    "official_title": "A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "zenocutuzumab (MCLA-128)"
      }
    ],
    "enrollment": 250,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-29"
  },
  "NCT04736706": {
    "nct_id": "NCT04736706",
    "brief_title": "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)",
    "official_title": "An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "Pembrolizumab"
      },
      {
        "type": "DRUG",
        "name": "Belzutifan"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Pembrolizumab/Quavonlimab"
      },
      {
        "type": "DRUG",
        "name": "Lenvatinib"
      }
    ],
    "enrollment": 1653,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-11-18"
  },
  "NCT03615326": {
    "nct_id": "NCT03615326",
    "brief_title": "Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)",
    "official_title": "A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "Pembrolizumab"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Placebo"
      },
      {
        "type": "DRUG",
        "name": "Cisplatin"
      },
      {
        "type": "DRUG",
        "name": "5-FU"
      },
      {
        "type": "DRUG",
        "name": "Oxaliplatin"
      },
      {
        "type": "DRUG",
        "name": "Capecitabine"
      },
      {
        "type": "DRUG",
        "name": "S-1"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Trastuzumab"
      }
    ],
    "enrollment": 738,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-17"
  },
  "NCT06143891": {
    "nct_id": "NCT06143891",
    "brief_title": "A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.",
    "official_title": "A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Belumosudil"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      },
      {
        "type": "DRUG",
        "name": "Prednisone"
      },
      {
        "type": "DRUG",
        "name": "Prednisolone"
      }
    ],
    "enrollment": 260,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-23"
  },
  "NCT05608291": {
    "nct_id": "NCT05608291",
    "brief_title": "A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery",
    "official_title": "A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Fianlimab"
      },
      {
        "type": "DRUG",
        "name": "Cemiplimab"
      },
      {
        "type": "DRUG",
        "name": "Pembrolizumab"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 1564,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-13"
  },
  "NCT06047080": {
    "nct_id": "NCT06047080",
    "brief_title": "An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma",
    "official_title": "A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Glofitamab"
      },
      {
        "type": "DRUG",
        "name": "Polatuzumab vedotin"
      },
      {
        "type": "DRUG",
        "name": "Rituximab"
      },
      {
        "type": "DRUG",
        "name": "Cyclophosphamide"
      },
      {
        "type": "DRUG",
        "name": "Doxorubicin"
      },
      {
        "type": "DRUG",
        "name": "Prednisone"
      }
    ],
    "enrollment": 1130,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-08"
  },
  "NCT05059262": {
    "nct_id": "NCT05059262",
    "brief_title": "Study of Vimseltinib for Tenosynovial Giant Cell Tumor",
    "official_title": "A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Vimseltinib"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 123,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-02-24"
  },
  "NCT03731260": {
    "nct_id": "NCT03731260",
    "brief_title": "(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis",
    "official_title": "A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Avapritinib"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 251,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-08-07"
  },
  "NCT05117476": {
    "nct_id": "NCT05117476",
    "brief_title": "A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors",
    "official_title": "A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "CLN-619"
      },
      {
        "type": "DRUG",
        "name": "Pembrolizumab"
      }
    ],
    "enrollment": 410,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-02-03"
  },
  "NCT06312176": {
    "nct_id": "NCT06312176",
    "brief_title": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)",
    "official_title": "An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Sacituzumab tirumotecan"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Pembrolizumab"
      },
      {
        "type": "DRUG",
        "name": "Paclitaxel"
      },
      {
        "type": "DRUG",
        "name": "Nab-paclitaxel"
      },
      {
        "type": "DRUG",
        "name": "Capecitabine"
      },
      {
        "type": "DRUG",
        "name": "Liposomal doxorubicin"
      }
    ],
    "enrollment": 1200,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-29"
  },
  "NCT04083976": {
    "nct_id": "NCT04083976",
    "brief_title": "A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations",
    "official_title": "A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Erdafitinib"
      }
    ],
    "enrollment": 316,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-22"
  },
  "NCT03975829": {
    "nct_id": "NCT03975829",
    "brief_title": "Pediatric Long-Term Follow-up and Rollover Study",
    "official_title": "An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "dabrafenib"
      },
      {
        "type": "DRUG",
        "name": "trametinib"
      }
    ],
    "enrollment": 163,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-24"
  },
  "NCT05563220": {
    "nct_id": "NCT05563220",
    "brief_title": "Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer",
    "official_title": "A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Elacestrant"
      },
      {
        "type": "DRUG",
        "name": "Alpelisib"
      },
      {
        "type": "DRUG",
        "name": "Everolimus"
      },
      {
        "type": "DRUG",
        "name": "Ribociclib"
      },
      {
        "type": "DRUG",
        "name": "Palbociclib"
      },
      {
        "type": "DRUG",
        "name": "Capivasertib"
      },
      {
        "type": "DRUG",
        "name": "Abemaciclib"
      }
    ],
    "enrollment": 400,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-02"
  },
  "NCT03301220": {
    "nct_id": "NCT03301220",
    "brief_title": "A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma",
    "official_title": "A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Daratumumab SC: daratumumab + rHuPH20"
      }
    ],
    "enrollment": 390,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-01"
  },
  "NCT02576431": {
    "nct_id": "NCT02576431",
    "brief_title": "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors",
    "official_title": "A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK Fusion",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "BAY2757556 (Larotrectinib, Vitrakvi)"
      }
    ],
    "enrollment": 215,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-27"
  },
  "NCT04681131": {
    "nct_id": "NCT04681131",
    "brief_title": "CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC",
    "official_title": "A Phase 2 Study of BA3011 Alone and in Combination with PD-1 Inhibitor in Adult Patients with Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, EGFR, or ALK Inhibitor.",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "CAB-AXL-ADC"
      },
      {
        "type": "BIOLOGICAL",
        "name": "PD-1 inhibitor"
      }
    ],
    "enrollment": 240,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-01-13"
  },
  "NCT02285582": {
    "nct_id": "NCT02285582",
    "brief_title": "International Rare Histiocytic Disorders Registry (IRHDR)",
    "official_title": "International Rare Histiocytic Disorders Registry (IRHDR)",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "OTHER",
        "name": "Registry study"
      }
    ],
    "enrollment": 400,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-24"
  },
  "NCT05975073": {
    "nct_id": "NCT05975073",
    "brief_title": "A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors",
    "official_title": "A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "AMG 193"
      },
      {
        "type": "DRUG",
        "name": "IDE397"
      }
    ],
    "enrollment": 53,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-02-27"
  },
  "NCT06782373": {
    "nct_id": "NCT06782373",
    "brief_title": "A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)",
    "official_title": "PAXIS: A Randomized, Double-blind, Placebo-controlled Dose-finding Phase 2 Study (Part 1) Followed by an Open-label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients With VEXAS Syndrome",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Pacritinib"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 78,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-05"
  },
  "NCT05552976": {
    "nct_id": "NCT05552976",
    "brief_title": "A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)",
    "official_title": "A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Mezigdomide"
      },
      {
        "type": "DRUG",
        "name": "Carfilzomib"
      },
      {
        "type": "DRUG",
        "name": "Dexamethasone"
      }
    ],
    "enrollment": 525,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-29"
  },
  "NCT04104776": {
    "nct_id": "NCT04104776",
    "brief_title": "A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas",
    "official_title": "A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Tulmimetostat"
      },
      {
        "type": "DRUG",
        "name": "Enzalutamide"
      }
    ],
    "enrollment": 275,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-15"
  },
  "NCT03260894": {
    "nct_id": "NCT03260894",
    "brief_title": "Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)",
    "official_title": "A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Pembrolizumab"
      },
      {
        "type": "DRUG",
        "name": "Epacadostat"
      },
      {
        "type": "DRUG",
        "name": "Sunitinib"
      },
      {
        "type": "DRUG",
        "name": "Pazopanib"
      }
    ],
    "enrollment": 129,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-02"
  },
  "NCT05580562": {
    "nct_id": "NCT05580562",
    "brief_title": "ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)",
    "official_title": "ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Dordaviprone (ONC201)"
      },
      {
        "type": "DRUG",
        "name": "Dordaviprone (ONC201) + Placebo"
      },
      {
        "type": "OTHER",
        "name": "Placebo"
      }
    ],
    "enrollment": 450,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-06"
  },
  "NCT06356129": {
    "nct_id": "NCT06356129",
    "brief_title": "Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma",
    "official_title": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Golcadomide"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      },
      {
        "type": "DRUG",
        "name": "Rituximab"
      },
      {
        "type": "DRUG",
        "name": "Cyclophosphamide"
      },
      {
        "type": "DRUG",
        "name": "Doxorubicin"
      },
      {
        "type": "DRUG",
        "name": "Vincristine"
      },
      {
        "type": "DRUG",
        "name": "Prednisone"
      }
    ],
    "enrollment": 850,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-12"
  },
  "NCT02513394": {
    "nct_id": "NCT02513394",
    "brief_title": "PALbociclib CoLlaborative Adjuvant Study",
    "official_title": "PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Palbociclib"
      },
      {
        "type": "DRUG",
        "name": "Standard Adjuvant Endocrine Therapy"
      }
    ],
    "enrollment": 5796,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-11"
  },
  "NCT02651662": {
    "nct_id": "NCT02651662",
    "brief_title": "A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies",
    "official_title": "A Phase 1 Study to Assess Safety and Tolerability of Odronextamab (REGN1979) an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, and Cemiplimab (REGN2810), an Anti-Programmed Death-1 Monoclonal Antibody in Patients With B-Cell Malignancies (CLIO-1)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "cemiplimab"
      },
      {
        "type": "DRUG",
        "name": "odronextamab"
      }
    ],
    "enrollment": 62,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-16"
  },
  "NCT03289962": {
    "nct_id": "NCT03289962",
    "brief_title": "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors",
    "official_title": "A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Autogene cevumeran"
      },
      {
        "type": "DRUG",
        "name": "Atezolizumab"
      }
    ],
    "enrollment": 272,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-24"
  },
  "NCT06179160": {
    "nct_id": "NCT06179160",
    "brief_title": "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",
    "official_title": "A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "INCB161734"
      },
      {
        "type": "DRUG",
        "name": "Cetuximab"
      },
      {
        "type": "DRUG",
        "name": "Retifanlimab"
      },
      {
        "type": "DRUG",
        "name": "GEMNabP"
      },
      {
        "type": "DRUG",
        "name": "mFOLFIRINOX"
      }
    ],
    "enrollment": 466,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-22"
  },
  "NCT03151629": {
    "nct_id": "NCT03151629",
    "brief_title": "International Registry for Men With Advanced Prostate Cancer (IRONMAN)",
    "official_title": "International Registry for Men With Advanced Prostate Cancer (IRONMAN)",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "OTHER",
        "name": "Standard of Care"
      }
    ],
    "enrollment": 5000,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-11-25"
  },
  "NCT03260491": {
    "nct_id": "NCT03260491",
    "brief_title": "U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer",
    "official_title": "A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "HER3-DXd (FL-DP)"
      },
      {
        "type": "DRUG",
        "name": "HER3-DXd (CTM-1 Lyo-DP)"
      },
      {
        "type": "DRUG",
        "name": "HER3-DXd (CTM-3 Lyo-DP)"
      }
    ],
    "enrollment": 309,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-27"
  },
  "NCT05557591": {
    "nct_id": "NCT05557591",
    "brief_title": "A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)",
    "official_title": "A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "BNT116"
      },
      {
        "type": "DRUG",
        "name": "Cemiplimab"
      }
    ],
    "enrollment": 100,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-06"
  },
  "NCT03734029": {
    "nct_id": "NCT03734029",
    "brief_title": "Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]",
    "official_title": "A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Trastuzumab deruxtecan (DS-8201a)"
      },
      {
        "type": "DRUG",
        "name": "Capecitabine"
      },
      {
        "type": "DRUG",
        "name": "Eribulin"
      },
      {
        "type": "DRUG",
        "name": "Gemcitabine"
      },
      {
        "type": "DRUG",
        "name": "Paclitaxel"
      },
      {
        "type": "DRUG",
        "name": "Nab-paclitaxel"
      }
    ],
    "enrollment": 557,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-04-11"
  },
  "NCT06435429": {
    "nct_id": "NCT06435429",
    "brief_title": "A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer",
    "official_title": "A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Zanidatamab"
      },
      {
        "type": "DRUG",
        "name": "Trastuzumab"
      },
      {
        "type": "DRUG",
        "name": "Eribulin"
      },
      {
        "type": "DRUG",
        "name": "Vinorelbine"
      },
      {
        "type": "DRUG",
        "name": "Gemcitabine"
      },
      {
        "type": "DRUG",
        "name": "Capecitabine"
      }
    ],
    "enrollment": 550,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-02"
  },
  "NCT05999994": {
    "nct_id": "NCT05999994",
    "brief_title": "A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer",
    "official_title": "CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Ramucirumab"
      },
      {
        "type": "DRUG",
        "name": "Cyclophosphamide"
      },
      {
        "type": "DRUG",
        "name": "Vinorelbine"
      },
      {
        "type": "DRUG",
        "name": "Gemcitabine"
      },
      {
        "type": "DRUG",
        "name": "Docetaxel"
      },
      {
        "type": "DRUG",
        "name": "Abemaciclib"
      },
      {
        "type": "DRUG",
        "name": "Irinotecan"
      },
      {
        "type": "DRUG",
        "name": "Temozolomide"
      }
    ],
    "enrollment": 105,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-21"
  },
  "NCT04585750": {
    "nct_id": "NCT04585750",
    "brief_title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)",
    "official_title": "A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "rezatapopt"
      },
      {
        "type": "DRUG",
        "name": "pembrolizumab"
      }
    ],
    "enrollment": 230,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-05"
  },
  "NCT04195750": {
    "nct_id": "NCT04195750",
    "brief_title": "A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)",
    "official_title": "An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Belzutifan"
      },
      {
        "type": "DRUG",
        "name": "Everolimus"
      }
    ],
    "enrollment": 755,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-29"
  },
  "NCT06703346": {
    "nct_id": "NCT06703346",
    "brief_title": "Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants with NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma",
    "official_title": "Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants with NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Experimental: Letetresgene autoleucel"
      }
    ],
    "enrollment": 87,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      },
      {
        "orpha_code": "699",
        "disease_name": "Pearson syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-11-25"
  },
  "NCT03805789": {
    "nct_id": "NCT03805789",
    "brief_title": "The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant",
    "official_title": "A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft-versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "AAT"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Placebo"
      }
    ],
    "enrollment": 310,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-17"
  },
  "NCT04619004": {
    "nct_id": "NCT04619004",
    "brief_title": "HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer",
    "official_title": "HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Patritumab Deruxtecan (Fixed dose)"
      },
      {
        "type": "DRUG",
        "name": "Patritumab Deruxtecan (Up-Titration)"
      }
    ],
    "enrollment": 277,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-20"
  },
  "NCT03969004": {
    "nct_id": "NCT03969004",
    "brief_title": "Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma",
    "official_title": "A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Cemiplimab"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 415,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-09-19"
  },
  "NCT02375204": {
    "nct_id": "NCT02375204",
    "brief_title": "Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors",
    "official_title": "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "paclitaxel"
      },
      {
        "type": "DRUG",
        "name": "ifosfamide"
      },
      {
        "type": "DRUG",
        "name": "cisplatin"
      },
      {
        "type": "DRUG",
        "name": "pegylated G-CSF"
      },
      {
        "type": "DRUG",
        "name": "G-CSF"
      },
      {
        "type": "DRUG",
        "name": "carboplatin"
      },
      {
        "type": "DRUG",
        "name": "etoposide phosphate"
      },
      {
        "type": "PROCEDURE",
        "name": "stem cell reinfusion"
      }
    ],
    "enrollment": 420,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-01-13"
  },
  "NCT04188548": {
    "nct_id": "NCT04188548",
    "brief_title": "A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer",
    "official_title": "EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "LY3484356"
      },
      {
        "type": "DRUG",
        "name": "Abemaciclib"
      },
      {
        "type": "DRUG",
        "name": "Everolimus"
      },
      {
        "type": "DRUG",
        "name": "Alpelisib"
      },
      {
        "type": "DRUG",
        "name": "Trastuzumab"
      },
      {
        "type": "DRUG",
        "name": "Aromatase Inhibitor (AI)"
      },
      {
        "type": "DRUG",
        "name": "Pertuzumab"
      }
    ],
    "enrollment": 500,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-04"
  },
  "NCT06003231": {
    "nct_id": "NCT06003231",
    "brief_title": "A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2",
    "official_title": "A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "disitamab vedotin"
      }
    ],
    "enrollment": 119,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-29"
  },
  "NCT06307431": {
    "nct_id": "NCT06307431",
    "brief_title": "A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).",
    "official_title": "A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004).",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "Intismeran autogene"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Pembrolizumab"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Placebo"
      }
    ],
    "enrollment": 272,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-13"
  },
  "NCT06026410": {
    "nct_id": "NCT06026410",
    "brief_title": "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors",
    "official_title": "Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "KO-2806"
      },
      {
        "type": "DRUG",
        "name": "Cabozantinib"
      },
      {
        "type": "DRUG",
        "name": "Adagrasib"
      }
    ],
    "enrollment": 270,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-13"
  },
  "NCT02503423": {
    "nct_id": "NCT02503423",
    "brief_title": "Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas",
    "official_title": "Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "ASTX660"
      }
    ],
    "enrollment": 230,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-01-07"
  },
  "NCT01594723": {
    "nct_id": "NCT01594723",
    "brief_title": "A Study of LY2784544 in Participants With Myeloproliferative Neoplasms",
    "official_title": "A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "120 mg LY2784544"
      }
    ],
    "enrollment": 110,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-20"
  },
  "NCT03967223": {
    "nct_id": "NCT03967223",
    "brief_title": "Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors",
    "official_title": "Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Letetresgene autoleucel (lete-cel, GSK3377794)"
      },
      {
        "type": "DRUG",
        "name": "Fludarabine"
      },
      {
        "type": "DRUG",
        "name": "Cyclophosphamide"
      }
    ],
    "enrollment": 103,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-10-15"
  },
  "NCT05573555": {
    "nct_id": "NCT05573555",
    "brief_title": "TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)",
    "official_title": "TACTIVE-U: AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 YEARS AND OVER WITH ER+ ADVANCED OR METASTATIC BREAST CANCER, SUB-STUDY B (ARV-471 IN COMBINATION WITH RIBOCICLIB)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "ARV-471"
      },
      {
        "type": "DRUG",
        "name": "Ribociclib"
      }
    ],
    "enrollment": 47,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-29"
  },
  "NCT05280314": {
    "nct_id": "NCT05280314",
    "brief_title": "Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors",
    "official_title": "Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Selected Resectable Tumors",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "IO102-IO103"
      },
      {
        "type": "DRUG",
        "name": "Pembrolizumab KEYTRUDA®"
      }
    ],
    "enrollment": 60,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-03-18"
  },
  "NCT04554914": {
    "nct_id": "NCT04554914",
    "brief_title": "A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases",
    "official_title": "An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein-Barr Virus-associated Diseases (EBVision)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "Tabelecleucel"
      }
    ],
    "enrollment": 190,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-11"
  },
  "NCT06112314": {
    "nct_id": "NCT06112314",
    "brief_title": "IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)",
    "official_title": "A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Brenetafusp"
      },
      {
        "type": "DRUG",
        "name": "Nivolumab"
      },
      {
        "type": "DRUG",
        "name": "Nivolumab + Relatlimab"
      }
    ],
    "enrollment": 680,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-04"
  },
  "NCT03650114": {
    "nct_id": "NCT03650114",
    "brief_title": "Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",
    "official_title": "An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "Ofatumumab"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Tetanus toxoid (TT) containing vaccine (Td, Tdap)"
      },
      {
        "type": "BIOLOGICAL",
        "name": "13-valent pneumococcal conjugate vaccine (13-PCV)"
      },
      {
        "type": "BIOLOGICAL",
        "name": "23-valent pneumococcal polysaccharide vaccine (23-PPV)"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Seasonal Quadrivalent influenza vaccine"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Keyhole limpet hemocyanin (KLH) neo-antigen"
      }
    ],
    "enrollment": 1882,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-04"
  },
  "NCT03108495": {
    "nct_id": "NCT03108495",
    "brief_title": "Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma",
    "official_title": "A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "LN-145"
      },
      {
        "type": "BIOLOGICAL",
        "name": "LN-145 + pembrolizumab"
      }
    ],
    "enrollment": 189,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-07"
  },
  "NCT05386108": {
    "nct_id": "NCT05386108",
    "brief_title": "Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer",
    "official_title": "An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Elacestrant"
      },
      {
        "type": "DRUG",
        "name": "Abemaciclib"
      }
    ],
    "enrollment": 68,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-08"
  },
  "NCT02032823": {
    "nct_id": "NCT02032823",
    "brief_title": "Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer",
    "official_title": "A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Olaparib"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 1837,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      },
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-08-23"
  },
  "NCT04662710": {
    "nct_id": "NCT04662710",
    "brief_title": "Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)",
    "official_title": "Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "Pembrolizumab"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Lenvatinib"
      },
      {
        "type": "DRUG",
        "name": "Oxaliplatin"
      },
      {
        "type": "DRUG",
        "name": "Capecitabine"
      },
      {
        "type": "DRUG",
        "name": "Leucovorin (or Levoleucovorin)"
      },
      {
        "type": "DRUG",
        "name": "5-FU"
      }
    ],
    "enrollment": 895,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-27"
  },
  "NCT05201781": {
    "nct_id": "NCT05201781",
    "brief_title": "A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel",
    "official_title": "Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Cilta-cel"
      }
    ],
    "enrollment": 228,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-23"
  },
  "NCT06203210": {
    "nct_id": "NCT06203210",
    "brief_title": "A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer",
    "official_title": "A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Ifinatamab deruxtecan"
      },
      {
        "type": "DRUG",
        "name": "Topotecan"
      },
      {
        "type": "DRUG",
        "name": "Amrubicin"
      },
      {
        "type": "DRUG",
        "name": "Lurbinectedin"
      }
    ],
    "enrollment": 540,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-04"
  },
  "NCT03786081": {
    "nct_id": "NCT03786081",
    "brief_title": "Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer",
    "official_title": "A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Tisotumab Vedotin"
      },
      {
        "type": "DRUG",
        "name": "Bevacizumab"
      },
      {
        "type": "DRUG",
        "name": "Pembrolizumab"
      },
      {
        "type": "DRUG",
        "name": "Carboplatin"
      }
    ],
    "enrollment": 214,
    "diseases": [
      {
        "orpha_code": "333",
        "disease_name": "Farber disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-10"
  },
  "NCT04176523": {
    "nct_id": "NCT04176523",
    "brief_title": "Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods Approach",
    "official_title": "Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods Approach",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Carglumic Acid"
      }
    ],
    "enrollment": 95,
    "diseases": [
      {
        "orpha_code": "35",
        "disease_name": "Propionic acidemia"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-02-05"
  },
  "NCT05769621": {
    "nct_id": "NCT05769621",
    "brief_title": "A Retrospective Study to Characterize Participants With Propionic Acidemia and Methylmalonic Acidemia",
    "official_title": "A Retrospective Cohort Study to Characterize Propionic Acidemia Patients and Methylmalonic Acidemia",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 200,
    "diseases": [
      {
        "orpha_code": "35",
        "disease_name": "Propionic acidemia"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-10-01"
  },
  "NCT05295433": {
    "nct_id": "NCT05295433",
    "brief_title": "An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705",
    "official_title": "A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "mRNA-3705"
      }
    ],
    "enrollment": 63,
    "diseases": [
      {
        "orpha_code": "35",
        "disease_name": "Propionic acidemia"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-13"
  },
  "NCT00358943": {
    "nct_id": "NCT00358943",
    "brief_title": "International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry",
    "official_title": "Gaucher Disease Registry Protocol",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 12000,
    "diseases": [
      {
        "orpha_code": "355",
        "disease_name": "Gaucher disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-11-20"
  },
  "NCT05641103": {
    "nct_id": "NCT05641103",
    "brief_title": "PREDIGA 2: Spanish Acronym of \"Educational and Diagnostic Project for Gaucher and ASMD\"",
    "official_title": "PREDIGA 2: Spanish Acronym of \"Educational and Diagnostic Project for Gaucher and ASMD\"",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "OTHER",
        "name": "Patient with splenomegaly or splenectomy"
      }
    ],
    "enrollment": 122,
    "diseases": [
      {
        "orpha_code": "355",
        "disease_name": "Gaucher disease"
      },
      {
        "orpha_code": "646",
        "disease_name": "Niemann-Pick disease type C"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-02-19"
  },
  "NCT05324943": {
    "nct_id": "NCT05324943",
    "brief_title": "A Gene Therapy Study in Patients With Gaucher Disease Type 1",
    "official_title": "A Phase 1, Open-label, Safety, Tolerability, and Efficacy Study of FLT201 in Adult Patients With Gaucher Disease Type 1 (GALILEO-1)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "GENETIC",
        "name": "FLT201"
      }
    ],
    "enrollment": 18,
    "diseases": [
      {
        "orpha_code": "355",
        "disease_name": "Gaucher disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-15"
  },
  "NCT05992532": {
    "nct_id": "NCT05992532",
    "brief_title": "GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma",
    "official_title": "GammaGA: Study of the Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 210,
    "diseases": [
      {
        "orpha_code": "355",
        "disease_name": "Gaucher disease"
      },
      {
        "orpha_code": "646",
        "disease_name": "Niemann-Pick disease type C"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-05-31"
  },
  "NCT06545136": {
    "nct_id": "NCT06545136",
    "brief_title": "Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)",
    "official_title": "A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT201) in Subjects With Gaucher Disease (GALILEO-2)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "GENETIC",
        "name": "FLT201"
      }
    ],
    "enrollment": 75,
    "diseases": [
      {
        "orpha_code": "355",
        "disease_name": "Gaucher disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-08-09"
  },
  "NCT05487599": {
    "nct_id": "NCT05487599",
    "brief_title": "A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)",
    "official_title": "An Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the Safety and Tolerability of a Single Intravenous Dose of LY3884961 in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "GENETIC",
        "name": "LY3884961"
      }
    ],
    "enrollment": 15,
    "diseases": [
      {
        "orpha_code": "355",
        "disease_name": "Gaucher disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-20"
  },
  "NCT03485677": {
    "nct_id": "NCT03485677",
    "brief_title": "Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3",
    "official_title": "Open Label, Two Cohort (With and Without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients With Gaucher Disease Type 1 and Type 3",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Eliglustat GZ385660"
      },
      {
        "type": "DRUG",
        "name": "Imiglucerase GZ437843"
      }
    ],
    "enrollment": 57,
    "diseases": [
      {
        "orpha_code": "355",
        "disease_name": "Gaucher disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-02-20"
  },
  "NCT06498128": {
    "nct_id": "NCT06498128",
    "brief_title": "Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®",
    "official_title": "QUVIVIQ® Pregnancy Registry",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Daridorexant"
      },
      {
        "type": "DRUG",
        "name": "Non-orexin receptor antagonist medications for insomnia"
      },
      {
        "type": "OTHER",
        "name": "No insomnia medication"
      }
    ],
    "enrollment": 785,
    "diseases": [
      {
        "orpha_code": "35710",
        "disease_name": "Glucose-galactose malabsorption"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-12-18"
  },
  "NCT04561518": {
    "nct_id": "NCT04561518",
    "brief_title": "ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)",
    "official_title": "ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 1500,
    "diseases": [
      {
        "orpha_code": "36386",
        "disease_name": "Hereditary sensory and autonomic neuropathy type 1"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-18"
  },
  "NCT05139316": {
    "nct_id": "NCT05139316",
    "brief_title": "A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)",
    "official_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "GENETIC",
        "name": "DTX401"
      },
      {
        "type": "OTHER",
        "name": "Placebo"
      },
      {
        "type": "DRUG",
        "name": "Oral corticosteroids"
      },
      {
        "type": "DRUG",
        "name": "Placebo for oral corticosteroids"
      }
    ],
    "enrollment": 49,
    "diseases": [
      {
        "orpha_code": "364",
        "disease_name": "Glycogen storage disease due to glucose-6-phosphatase deficiency"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-02-21"
  },
  "NCT05682378": {
    "nct_id": "NCT05682378",
    "brief_title": "Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies",
    "official_title": "An Open-label, Single Arm, Multicenter Extension Study to Evaluate Long-term Safety and Tolerability of Inclisiran in Participants With Heterozygous or Homozygous Familial Hypercholesterolemia Who Have Completed the Adolescent ORION-16 or ORION-13 Studies (VICTORION-PEDS-OLE)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Inclisiran"
      }
    ],
    "enrollment": 154,
    "diseases": [
      {
        "orpha_code": "391665",
        "disease_name": "Homozygous familial hypercholesterolemia"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-19"
  },
  "NCT04370899": {
    "nct_id": "NCT04370899",
    "brief_title": "Early Detection of Familial Hypercholesterolemia in Children",
    "official_title": "Early Detection of Familial Hypercholesterolemia in Children in Tarragona Province",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "OTHER",
        "name": "lifestyle assessment"
      }
    ],
    "enrollment": 400,
    "diseases": [
      {
        "orpha_code": "391665",
        "disease_name": "Homozygous familial hypercholesterolemia"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-18"
  },
  "NCT04580420": {
    "nct_id": "NCT04580420",
    "brief_title": "Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD",
    "official_title": "A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "DCR-PHXC"
      }
    ],
    "enrollment": 28,
    "diseases": [
      {
        "orpha_code": "416",
        "disease_name": "Primary hyperoxaluria"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-15"
  },
  "NCT04042402": {
    "nct_id": "NCT04042402",
    "brief_title": "Long Term Extension Study in Patients With Primary Hyperoxaluria",
    "official_title": "An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "DCR-PHXC"
      }
    ],
    "enrollment": 75,
    "diseases": [
      {
        "orpha_code": "416",
        "disease_name": "Primary hyperoxaluria"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-30"
  },
  "NCT04982393": {
    "nct_id": "NCT04982393",
    "brief_title": "BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)",
    "official_title": "BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 200,
    "diseases": [
      {
        "orpha_code": "416",
        "disease_name": "Primary hyperoxaluria"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-13"
  },
  "NCT05819866": {
    "nct_id": "NCT05819866",
    "brief_title": "A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy",
    "official_title": "A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Leriglitazone"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 40,
    "diseases": [
      {
        "orpha_code": "43",
        "disease_name": "X-linked adrenoleukodystrophy"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-08"
  },
  "NCT06513533": {
    "nct_id": "NCT06513533",
    "brief_title": "Dimethyl Fumarate in Adrenomyeloneuropathy",
    "official_title": "Effect of Dimethyl Fumarate Administered to Patients With Adrenomyeloneuropathy: a Multicenter, Placebo Controlled, Phase IIb/III Trial",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "OTHER",
        "name": "Placebo"
      },
      {
        "type": "DRUG",
        "name": "Dimethyl fumarate"
      }
    ],
    "enrollment": 40,
    "diseases": [
      {
        "orpha_code": "43",
        "disease_name": "X-linked adrenoleukodystrophy"
      },
      {
        "orpha_code": "588",
        "disease_name": "Muscle-eye-brain disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-07-25"
  },
  "NCT06144840": {
    "nct_id": "NCT06144840",
    "brief_title": "INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP",
    "official_title": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Dersimelagon"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 165,
    "diseases": [
      {
        "orpha_code": "443197",
        "disease_name": "X-linked erythropoietic protoporphyria"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-18"
  },
  "NCT05005975": {
    "nct_id": "NCT05005975",
    "brief_title": "Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)",
    "official_title": "A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "MT-7117"
      }
    ],
    "enrollment": 301,
    "diseases": [
      {
        "orpha_code": "443197",
        "disease_name": "X-linked erythropoietic protoporphyria"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-22"
  },
  "NCT05130450": {
    "nct_id": "NCT05130450",
    "brief_title": "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)",
    "official_title": "An Open-Label Extension Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Olezarsen"
      }
    ],
    "enrollment": 60,
    "diseases": [
      {
        "orpha_code": "444490",
        "disease_name": "Familial chylomicronemia syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-04"
  },
  "NCT05089084": {
    "nct_id": "NCT05089084",
    "brief_title": "Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)",
    "official_title": "A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Plozasiran"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 75,
    "diseases": [
      {
        "orpha_code": "444490",
        "disease_name": "Familial chylomicronemia syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-30"
  },
  "NCT05133531": {
    "nct_id": "NCT05133531",
    "brief_title": "A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment",
    "official_title": "A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Ravulizumab"
      },
      {
        "type": "DRUG",
        "name": "Pozelimab"
      },
      {
        "type": "DRUG",
        "name": "Cemdisiran"
      },
      {
        "type": "DRUG",
        "name": "Eculizumab"
      }
    ],
    "enrollment": 190,
    "diseases": [
      {
        "orpha_code": "447",
        "disease_name": "Paroxysmal nocturnal hemoglobinuria"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-06"
  },
  "NCT05741346": {
    "nct_id": "NCT05741346",
    "brief_title": "Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria",
    "official_title": "An Open-label Study to Evaluate the Long-term Safety of BCX9930 Monotherapy in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Previously Received BCX9930 in a BioCryst-sponsored Study",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "BCX9930"
      }
    ],
    "enrollment": 28,
    "diseases": [
      {
        "orpha_code": "447",
        "disease_name": "Paroxysmal nocturnal hemoglobinuria"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-07-29"
  },
  "NCT04434092": {
    "nct_id": "NCT04434092",
    "brief_title": "A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors",
    "official_title": "A Phase III, Randomized, Open-label, Active-controlled, Multicenter Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Crovalimab"
      },
      {
        "type": "DRUG",
        "name": "Eculizumab"
      }
    ],
    "enrollment": 204,
    "diseases": [
      {
        "orpha_code": "447",
        "disease_name": "Paroxysmal nocturnal hemoglobinuria"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-01"
  },
  "NCT05776472": {
    "nct_id": "NCT05776472",
    "brief_title": "A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)",
    "official_title": "A Single Arm, Long-term, Multicentre Observational Study to Evaluate Effectiveness of Pegcetacoplan Under Real World Conditions in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Pegcetacoplan"
      }
    ],
    "enrollment": 200,
    "diseases": [
      {
        "orpha_code": "447",
        "disease_name": "Paroxysmal nocturnal hemoglobinuria"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-14"
  },
  "NCT05744921": {
    "nct_id": "NCT05744921",
    "brief_title": "A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works",
    "official_title": "An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Pozelimab"
      },
      {
        "type": "DRUG",
        "name": "Cemdisiran"
      }
    ],
    "enrollment": 202,
    "diseases": [
      {
        "orpha_code": "447",
        "disease_name": "Paroxysmal nocturnal hemoglobinuria"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-25"
  },
  "NCT04432584": {
    "nct_id": "NCT04432584",
    "brief_title": "A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors",
    "official_title": "A Phase III, Randomized, Open-label, Active-controlled, Multicenter Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamic and Efficacy of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Crovalimab"
      },
      {
        "type": "DRUG",
        "name": "Eculizumab"
      }
    ],
    "enrollment": 190,
    "diseases": [
      {
        "orpha_code": "447",
        "disease_name": "Paroxysmal nocturnal hemoglobinuria"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-04"
  },
  "NCT03531255": {
    "nct_id": "NCT03531255",
    "brief_title": "Pegcetacoplan Long Term Safety and Efficacy Extension Study",
    "official_title": "An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Pegcetacoplan"
      }
    ],
    "enrollment": 160,
    "diseases": [
      {
        "orpha_code": "447",
        "disease_name": "Paroxysmal nocturnal hemoglobinuria"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-28"
  },
  "NCT04747613": {
    "nct_id": "NCT04747613",
    "brief_title": "Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria",
    "official_title": "An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PNH Phase 2 and Phase3 Studies With Iptacopan",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Iptacopan"
      }
    ],
    "enrollment": 208,
    "diseases": [
      {
        "orpha_code": "447",
        "disease_name": "Paroxysmal nocturnal hemoglobinuria"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-19"
  },
  "NCT04901936": {
    "nct_id": "NCT04901936",
    "brief_title": "A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)",
    "official_title": "An Open Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Biologic Activity of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Pegcetacoplan"
      }
    ],
    "enrollment": 12,
    "diseases": [
      {
        "orpha_code": "447",
        "disease_name": "Paroxysmal nocturnal hemoglobinuria"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-11"
  },
  "NCT05389449": {
    "nct_id": "NCT05389449",
    "brief_title": "A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH",
    "official_title": "A Long-term Extension (LTE) Study to Characterize the Safety and Efficacy of Danicopan as an Add-on Therapy to a Complement Component 5 Inhibitor (C5i) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Previously Treated With Danicopan in an Alexion-sponsored Clinical Study",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Danicopan"
      }
    ],
    "enrollment": 80,
    "diseases": [
      {
        "orpha_code": "447",
        "disease_name": "Paroxysmal nocturnal hemoglobinuria"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-22"
  },
  "NCT04641741": {
    "nct_id": "NCT04641741",
    "brief_title": "Effect of Mepolizumab on Severe Eosinophilic Asthma",
    "official_title": "Effect of Mepolizumab on the Phenotype/Proteome/Transcriptome of Eosinophils in Severe Eosinophilic Asthma",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Mepolizumab 100 MG"
      }
    ],
    "enrollment": 30,
    "diseases": [
      {
        "orpha_code": "510",
        "disease_name": "Lesch-Nyhan syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2023-09-25"
  },
  "NCT03771898": {
    "nct_id": "NCT03771898",
    "brief_title": "A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy",
    "official_title": "A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "SHP611"
      }
    ],
    "enrollment": 36,
    "diseases": [
      {
        "orpha_code": "512",
        "disease_name": "Metachromatic leukodystrophy"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-07"
  },
  "NCT04940572": {
    "nct_id": "NCT04940572",
    "brief_title": "Efficacy Study of Daily Administration of VPA in Patients Affected by Wolfram Syndrome",
    "official_title": "AUDIOWOLF: A Phase II, Open-label, Efficacy Study of Daily Administration of Sodium Valproate in Patients Clinically Affected by Wolfram Syndrome Due to Monogenic Mutation.",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Depakine"
      }
    ],
    "enrollment": 23,
    "diseases": [
      {
        "orpha_code": "542585",
        "disease_name": "Auditory neuropathy-optic atrophy syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2023-11-28"
  },
  "NCT06685835": {
    "nct_id": "NCT06685835",
    "brief_title": "A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)",
    "official_title": "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa - The CEDAR Study",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Brensocatib"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 204,
    "diseases": [
      {
        "orpha_code": "550",
        "disease_name": "MELAS"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-29"
  },
  "NCT06028230": {
    "nct_id": "NCT06028230",
    "brief_title": "A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa",
    "official_title": "A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "SAR444656 (KT-474)"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 156,
    "diseases": [
      {
        "orpha_code": "550",
        "disease_name": "MELAS"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-22"
  },
  "NCT05581004": {
    "nct_id": "NCT05581004",
    "brief_title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors",
    "official_title": "A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "RO7502175"
      },
      {
        "type": "DRUG",
        "name": "Atezolizumab"
      },
      {
        "type": "DRUG",
        "name": "Pembrolizumab"
      }
    ],
    "enrollment": 450,
    "diseases": [
      {
        "orpha_code": "550",
        "disease_name": "MELAS"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-22"
  },
  "NCT05255328": {
    "nct_id": "NCT05255328",
    "brief_title": "Clinical Long Term Evaluation of Glutamine Supplement in MELAS Syndrome",
    "official_title": "Clinical Long Term Evaluation of Glutamine Supplement in MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) Syndrome in Order to Prevent Neurological Damage.",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "DIETARY_SUPPLEMENT",
        "name": "Glutamine oral supplement"
      }
    ],
    "enrollment": 9,
    "diseases": [
      {
        "orpha_code": "550",
        "disease_name": "MELAS"
      }
    ],
    "locations_spain": true,
    "last_update": "2023-09-28"
  },
  "NCT05150704": {
    "nct_id": "NCT05150704",
    "brief_title": "MYTHS - MYocarditis THerapy With Steroids",
    "official_title": "Single Blind Randomized Controlled Trial to Assess the Safety and Efficacy of High Dose Pulse Intravenous Corticosteroid Therapy to Treat Patients With Complicated/Fulminant Acute Myocarditis",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Methylprednisolone"
      },
      {
        "type": "DRUG",
        "name": "saline solution"
      }
    ],
    "enrollment": 288,
    "diseases": [
      {
        "orpha_code": "578",
        "disease_name": "Mucolipidosis type IV"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-12-13"
  },
  "NCT05947851": {
    "nct_id": "NCT05947851",
    "brief_title": "A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).",
    "official_title": "A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Nemtabrutinib"
      },
      {
        "type": "DRUG",
        "name": "Venetoclax"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Rituximab"
      }
    ],
    "enrollment": 720,
    "diseases": [
      {
        "orpha_code": "578",
        "disease_name": "Mucolipidosis type IV"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-29"
  },
  "NCT02716246": {
    "nct_id": "NCT02716246",
    "brief_title": "Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH",
    "official_title": "Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "UX111"
      },
      {
        "type": "DRUG",
        "name": "Prophylactic Immunomodulatory (IM) Therapy"
      },
      {
        "type": "DRUG",
        "name": "Optimized Prophylactic IM Therapy"
      },
      {
        "type": "DRUG",
        "name": "Adjuvant IM Therapy"
      }
    ],
    "enrollment": 36,
    "diseases": [
      {
        "orpha_code": "579",
        "disease_name": "Mucopolysaccharidosis type 1"
      },
      {
        "orpha_code": "580",
        "disease_name": "Mucopolysaccharidosis type 2"
      },
      {
        "orpha_code": "581",
        "disease_name": "Mucopolysaccharidosis type 3"
      },
      {
        "orpha_code": "582",
        "disease_name": "Mucopolysaccharidosis type 4"
      },
      {
        "orpha_code": "662216",
        "disease_name": "Mucopolysaccharidosis type 10"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-15"
  },
  "NCT04573023": {
    "nct_id": "NCT04573023",
    "brief_title": "A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)",
    "official_title": "A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "JR-141"
      },
      {
        "type": "DRUG",
        "name": "Idursulfase"
      },
      {
        "type": "DRUG",
        "name": "JR-141 or Idursulfase"
      }
    ],
    "enrollment": 80,
    "diseases": [
      {
        "orpha_code": "580",
        "disease_name": "Mucopolysaccharidosis type 2"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-16"
  },
  "NCT05371613": {
    "nct_id": "NCT05371613",
    "brief_title": "A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)",
    "official_title": "A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "tividenofusp alfa"
      },
      {
        "type": "DRUG",
        "name": "idursulfase"
      }
    ],
    "enrollment": 54,
    "diseases": [
      {
        "orpha_code": "580",
        "disease_name": "Mucopolysaccharidosis type 2"
      },
      {
        "orpha_code": "581",
        "disease_name": "Mucopolysaccharidosis type 3"
      },
      {
        "orpha_code": "583",
        "disease_name": "Mucopolysaccharidosis type 6"
      },
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-03"
  },
  "NCT03604835": {
    "nct_id": "NCT03604835",
    "brief_title": "Mucopolysaccharidosis VII Disease Monitoring Program",
    "official_title": "Mucopolysaccharidosis VII Disease Monitoring Program (MPS VII DMP)",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "OTHER",
        "name": "No Intervention"
      }
    ],
    "enrollment": 50,
    "diseases": [
      {
        "orpha_code": "584",
        "disease_name": "Mucopolysaccharidosis type 7"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-27"
  },
  "NCT06925022": {
    "nct_id": "NCT06925022",
    "brief_title": "Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: The ADVICE Protocol Study (Phase 1)",
    "official_title": "Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: The ADVICE Protocol Study",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "OTHER",
        "name": "Strength training session during Early Follicular Phase"
      },
      {
        "type": "OTHER",
        "name": "Strength Training Protocol during Late Follicular Phase"
      },
      {
        "type": "OTHER",
        "name": "Strength Training during Mid-Luteal Phase"
      }
    ],
    "enrollment": 30,
    "diseases": [
      {
        "orpha_code": "588",
        "disease_name": "Muscle-eye-brain disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-08"
  },
  "NCT06839482": {
    "nct_id": "NCT06839482",
    "brief_title": "Robotic Rehabilitation of the Upper Limb in Subacute Stroke",
    "official_title": "Efficacy of Robotic Rehabilitation for Neuro Recovery of the Upper Limb in Subacute Stroke Survivors: An International Multicenter Randomized Controlled Trial",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "DEVICE",
        "name": "Robotic Assisted Upper Limb Rehabilitation"
      },
      {
        "type": "OTHER",
        "name": "Control Group (CG)"
      }
    ],
    "enrollment": 130,
    "diseases": [
      {
        "orpha_code": "588",
        "disease_name": "Muscle-eye-brain disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-02-24"
  },
  "NCT06965660": {
    "nct_id": "NCT06965660",
    "brief_title": "Population Cohort Set-up for the Epidemiological Assessment of Balance Disorders in Elderly People",
    "official_title": "Prevalence and Burden of Balance Disorders in Community-dwelling Older Adults: A Population-based Study Protocol",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 1300,
    "diseases": [
      {
        "orpha_code": "588",
        "disease_name": "Muscle-eye-brain disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-11"
  },
  "NCT07040748": {
    "nct_id": "NCT07040748",
    "brief_title": "Immersive Virtual Reality Training for Improving Cognition in Adults With Metabolic Syndrome",
    "official_title": "Multimodal Immersive Virtual Reality Training for Improving Cognition in Adults With Metabolic Syndrome: A Randomized Clinical Trial",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "BEHAVIORAL",
        "name": "Immersive VR-Based Multimodal Intervention (Virtual-METS)"
      }
    ],
    "enrollment": 84,
    "diseases": [
      {
        "orpha_code": "588",
        "disease_name": "Muscle-eye-brain disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-27"
  },
  "NCT06884579": {
    "nct_id": "NCT06884579",
    "brief_title": "Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: the ADVICE Protocol Study (Phase 2)",
    "official_title": "Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: The ADVICE Protocol Study",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "OTHER",
        "name": "Strength training, nutrition, and behavioral training"
      },
      {
        "type": "OTHER",
        "name": "Self-Guided and Unsupervised Program with General Recommendations"
      }
    ],
    "enrollment": 60,
    "diseases": [
      {
        "orpha_code": "588",
        "disease_name": "Muscle-eye-brain disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-06"
  },
  "NCT04084795": {
    "nct_id": "NCT04084795",
    "brief_title": "Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia",
    "official_title": "Augmentation of EMDR With Transcranial Direct Current Stimulation in the Treatment of Fibromyalgia: a Randomized Controlled Trial",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "BEHAVIORAL",
        "name": "Eye Movement Desensitization and Reprocessing therapy"
      },
      {
        "type": "OTHER",
        "name": "Multifocal transcranial Current Stimulation"
      }
    ],
    "enrollment": 96,
    "diseases": [
      {
        "orpha_code": "588",
        "disease_name": "Muscle-eye-brain disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-04-03"
  },
  "NCT07025070": {
    "nct_id": "NCT07025070",
    "brief_title": "The Link Between Physical Activity and Brain Health in Healthy Adults",
    "official_title": "The Link Between Strength and Endurance Training and Brain Health in Healthy Adults: A Comparative Study of Former Professional Athletes and Sedentary Individuals",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 60,
    "diseases": [
      {
        "orpha_code": "588",
        "disease_name": "Muscle-eye-brain disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-17"
  },
  "NCT03889132": {
    "nct_id": "NCT03889132",
    "brief_title": "Glucose, Brain and Microbiota",
    "official_title": "Integrated Analysis of the Interactions Between Glycemia and Microbiota Composition, and Their Impact on Brain Iron Deposition and Cognition in Subjects With Obesity",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "PROCEDURE",
        "name": "Bariatric Surgery"
      }
    ],
    "enrollment": 128,
    "diseases": [
      {
        "orpha_code": "588",
        "disease_name": "Muscle-eye-brain disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-03-08"
  },
  "NCT02983370": {
    "nct_id": "NCT02983370",
    "brief_title": "Development of a Cortical Visual Neuroprosthesis for the Blind",
    "official_title": "Pilot Study for the Development of a Cortical Visual Neuroprosthesis for the Blind Based on Intracortical Microelectrodes",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "PROCEDURE",
        "name": "Minicraniotomy"
      }
    ],
    "enrollment": 5,
    "diseases": [
      {
        "orpha_code": "588",
        "disease_name": "Muscle-eye-brain disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-05-08"
  },
  "NCT06149897": {
    "nct_id": "NCT06149897",
    "brief_title": "Feasibility and Effectiveness of tDCS in the Treatment of Post-stroke Fatigue (EFECTS).",
    "official_title": "Feasibility and Effectiveness of Tdcs in a Multimodal Treatment With Health Education and Aerobic Exercise in the Treatment of Post-stroke Fatigue.",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "DEVICE",
        "name": "tDCS"
      }
    ],
    "enrollment": 54,
    "diseases": [
      {
        "orpha_code": "588",
        "disease_name": "Muscle-eye-brain disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2023-11-29"
  },
  "NCT02726386": {
    "nct_id": "NCT02726386",
    "brief_title": "A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease",
    "official_title": "A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "ND0612"
      }
    ],
    "enrollment": 214,
    "diseases": [
      {
        "orpha_code": "611237",
        "disease_name": "Parkinsonism with polyneuropathy"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-30"
  },
  "NCT04379050": {
    "nct_id": "NCT04379050",
    "brief_title": "Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease",
    "official_title": "An Open-label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "ABBV-951"
      }
    ],
    "enrollment": 130,
    "diseases": [
      {
        "orpha_code": "611237",
        "disease_name": "Parkinsonism with polyneuropathy"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-06-18"
  },
  "NCT04860960": {
    "nct_id": "NCT04860960",
    "brief_title": "Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1",
    "official_title": "Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of 2000mg/kg of Trappsol®Cyclo™ (Hydroxypropyl-B-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients With Niemann-Pick Disease Type C1 (TransportNPC)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Hydroxypropyl-beta-cyclodextrin"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 94,
    "diseases": [
      {
        "orpha_code": "646",
        "disease_name": "Niemann-Pick disease type C"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-06-04"
  },
  "NCT05162768": {
    "nct_id": "NCT05162768",
    "brief_title": "Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)",
    "official_title": "A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPower",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Elamipretide"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 102,
    "diseases": [
      {
        "orpha_code": "663",
        "disease_name": "Mitochondrial DNA-related progressive external ophthalmoplegia"
      }
    ],
    "locations_spain": true,
    "last_update": "2023-12-12"
  },
  "NCT06255782": {
    "nct_id": "NCT06255782",
    "brief_title": "An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency",
    "official_title": "A Phase 1/2/3 First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of a Single Intravenous (IV) Administration of ECUR-506 in Males Less Than 9 Months of Age With Genetically Confirmed Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "GENETIC",
        "name": "ECUR-506"
      }
    ],
    "enrollment": 8,
    "diseases": [
      {
        "orpha_code": "664",
        "disease_name": "Ornithine transcarbamylase deficiency"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-15"
  },
  "NCT03636438": {
    "nct_id": "NCT03636438",
    "brief_title": "Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency",
    "official_title": "A Long-Term Follow-up Study to Evaluate Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults With Late-Onset OTC Deficiency",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "OTHER",
        "name": "No Intervention"
      }
    ],
    "enrollment": 11,
    "diseases": [
      {
        "orpha_code": "664",
        "disease_name": "Ornithine transcarbamylase deficiency"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-02"
  },
  "NCT05345171": {
    "nct_id": "NCT05345171",
    "brief_title": "Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency",
    "official_title": "A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adeno-associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Patients With Late-onset OTC Deficiency",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "GENETIC",
        "name": "DTX301"
      },
      {
        "type": "OTHER",
        "name": "Placebo"
      },
      {
        "type": "DRUG",
        "name": "Oral Corticosteroids"
      },
      {
        "type": "DRUG",
        "name": "Placebo for oral corticosteroids"
      },
      {
        "type": "DRUG",
        "name": "Sodium Acetate"
      }
    ],
    "enrollment": 32,
    "diseases": [
      {
        "orpha_code": "664",
        "disease_name": "Ornithine transcarbamylase deficiency"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-15"
  },
  "NCT05755035": {
    "nct_id": "NCT05755035",
    "brief_title": "A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases",
    "official_title": "Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "TAK-881"
      },
      {
        "type": "BIOLOGICAL",
        "name": "HYQVIA"
      }
    ],
    "enrollment": 65,
    "diseases": [
      {
        "orpha_code": "67041",
        "disease_name": "Hyaluronidase deficiency"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-13"
  },
  "NCT04998812": {
    "nct_id": "NCT04998812",
    "brief_title": "A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy",
    "official_title": "A Phase IV Multicenter, Open-Label Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Ocrelizumab"
      }
    ],
    "enrollment": 70,
    "diseases": [
      {
        "orpha_code": "699",
        "disease_name": "Pearson syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-22"
  },
  "NCT06521996": {
    "nct_id": "NCT06521996",
    "brief_title": "M-CHOP in Richter´s Syndrome",
    "official_title": "CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish CLL Group",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "Mosunetuzumab"
      },
      {
        "type": "DRUG",
        "name": "CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)"
      }
    ],
    "enrollment": 34,
    "diseases": [
      {
        "orpha_code": "699",
        "disease_name": "Pearson syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-07-26"
  },
  "NCT02598661": {
    "nct_id": "NCT02598661",
    "brief_title": "Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)",
    "official_title": "A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Imetelstat Sodium"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 289,
    "diseases": [
      {
        "orpha_code": "699",
        "disease_name": "Pearson syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-30"
  },
  "NCT05929066": {
    "nct_id": "NCT05929066",
    "brief_title": "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight",
    "official_title": "A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Retatrutide"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 2300,
    "diseases": [
      {
        "orpha_code": "709",
        "disease_name": "Peters plus syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-18"
  },
  "NCT05929079": {
    "nct_id": "NCT05929079",
    "brief_title": "A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight",
    "official_title": "A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Retatrutide"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 1000,
    "diseases": [
      {
        "orpha_code": "709",
        "disease_name": "Peters plus syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-18"
  },
  "NCT06423651": {
    "nct_id": "NCT06423651",
    "brief_title": "Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders",
    "official_title": "Benefits of Combining Metacognitive Training (MCT) With Cognitive Remediation (CR) in the Recovery of Patients With Psychotic Spectrum Disorders (CR+MCTp)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "BEHAVIORAL",
        "name": "Cognitive Remediation (REHACOP)"
      },
      {
        "type": "BEHAVIORAL",
        "name": "Metacognitive Training (MCT)"
      }
    ],
    "enrollment": 160,
    "diseases": [
      {
        "orpha_code": "709",
        "disease_name": "Peters plus syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-05-23"
  },
  "NCT05455593": {
    "nct_id": "NCT05455593",
    "brief_title": "Effectiveness of the Combination of Water Aerobics and Metacognitive Training",
    "official_title": "Efficacy of the Combination of Water Aerobics and Metacognitive Training (MCT) on Psychological and Physical Health Variables and Their Relationship With SP1 and SP4 Biomarkers in People With Psychosis",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "BEHAVIORAL",
        "name": "Water aerobics"
      },
      {
        "type": "BEHAVIORAL",
        "name": "Metacognitive Training (MCT)"
      },
      {
        "type": "BEHAVIORAL",
        "name": "Combined intervention"
      }
    ],
    "enrollment": 50,
    "diseases": [
      {
        "orpha_code": "709",
        "disease_name": "Peters plus syndrome"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-08-22"
  },
  "NCT05166161": {
    "nct_id": "NCT05166161",
    "brief_title": "A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria",
    "official_title": "A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "PTC923"
      }
    ],
    "enrollment": 200,
    "diseases": [
      {
        "orpha_code": "716",
        "disease_name": "Phenylketonuria"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-08"
  },
  "NCT05175105": {
    "nct_id": "NCT05175105",
    "brief_title": "A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period",
    "official_title": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused, Followed by a 5-Year Open-label Extension Period",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Mitapivat"
      },
      {
        "type": "DRUG",
        "name": "Mitapivat-matching placebo"
      }
    ],
    "enrollment": 30,
    "diseases": [
      {
        "orpha_code": "765",
        "disease_name": "Pyruvate dehydrogenase deficiency"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-22"
  },
  "NCT06213402": {
    "nct_id": "NCT06213402",
    "brief_title": "RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)",
    "official_title": "A Retrospective/Prospective, Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs) With Clinical Significance.",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "OTHER",
        "name": "Data collection from EHR."
      }
    ],
    "enrollment": 32564,
    "diseases": [
      {
        "orpha_code": "766",
        "disease_name": "Hemolytic anemia due to red cell pyruvate kinase deficiency"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-01-19"
  },
  "NCT04526665": {
    "nct_id": "NCT04526665",
    "brief_title": "Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)",
    "official_title": "A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Elafibranor 80mg"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 161,
    "diseases": [
      {
        "orpha_code": "79095",
        "disease_name": "Congenital bile acid synthesis defect type 4"
      },
      {
        "orpha_code": "79301",
        "disease_name": "Congenital bile acid synthesis defect type 1"
      },
      {
        "orpha_code": "79302",
        "disease_name": "Congenital bile acid synthesis defect type 3"
      },
      {
        "orpha_code": "79303",
        "disease_name": "Congenital bile acid synthesis defect type 2"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-22"
  },
  "NCT05549219": {
    "nct_id": "NCT05549219",
    "brief_title": "24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG",
    "official_title": "A Phase 2, Randomized, Open-Label, 24-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult, Adolescent, and Pediatric Participants With PMM2-CDG",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "GLM101"
      }
    ],
    "enrollment": 44,
    "diseases": [
      {
        "orpha_code": "79318",
        "disease_name": "PMM2-CDG"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-31"
  },
  "NCT03173300": {
    "nct_id": "NCT03173300",
    "brief_title": "Natural History Study Protocol in PMM2-CDG (CDG-Ia)",
    "official_title": "Clinical and Basic Investigations Into Phosphomannomutase Deficiency (PMM2-CDG)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 120,
    "diseases": [
      {
        "orpha_code": "79318",
        "disease_name": "PMM2-CDG"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-04"
  },
  "NCT05860816": {
    "nct_id": "NCT05860816",
    "brief_title": "Facilitators and Barriers in Neuroscience-based Pain Education Programmes in Primary Care Physiotherapy",
    "official_title": "Facilitators and Barriers to Implementing Pain Neuroscience Education Programmes for the Treatment of Patients With Chronic Pain in Primary Care Physiotherapy Units: the Physiotherapist's Perspective",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "OTHER",
        "name": "Survey"
      }
    ],
    "enrollment": 123,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-02-17"
  },
  "NCT05507216": {
    "nct_id": "NCT05507216",
    "brief_title": "ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2",
    "official_title": "A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "ABX464"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 612,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-07-26"
  },
  "NCT06151574": {
    "nct_id": "NCT06151574",
    "brief_title": "Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment",
    "official_title": "Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "zongertinib"
      },
      {
        "type": "DRUG",
        "name": "pembrolizumab"
      },
      {
        "type": "DRUG",
        "name": "cisplatin"
      },
      {
        "type": "DRUG",
        "name": "carboplatin"
      },
      {
        "type": "DRUG",
        "name": "pemetrexed"
      }
    ],
    "enrollment": 416,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-27"
  },
  "NCT05085366": {
    "nct_id": "NCT05085366",
    "brief_title": "A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age",
    "official_title": "A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "mRNA-1647"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Placebo"
      }
    ],
    "enrollment": 7454,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-12-24"
  },
  "NCT05239858": {
    "nct_id": "NCT05239858",
    "brief_title": "International Wilson's Disease Patient Registry (iWilson Registry)",
    "official_title": "International Wilson's Disease Patient Registry (iWilson Registry)",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 500,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-03"
  },
  "NCT05890729": {
    "nct_id": "NCT05890729",
    "brief_title": "A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis",
    "official_title": "A Seamless, Phase 1b/2 Multiple Ascending Dose/Proof of Concept Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "XTMAB-16 or Placebo"
      }
    ],
    "enrollment": 94,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-06"
  },
  "NCT05917327": {
    "nct_id": "NCT05917327",
    "brief_title": "Performance and Safety of MEX-CD1 Low-volume Continuous Veno-venous Haemodialysis Medical Device for Copper-extraction in Patients With Wilson's Disease",
    "official_title": "MEXWILS - Performance and Safety of MEX-CD1 Low-volume Continuous Veno-venous Haemodialysis Medical Device for Copper-extraction in Patients With Wilson's Disease",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "DEVICE",
        "name": "Low-volume continuous veno-venous haemodialysis"
      }
    ],
    "enrollment": 17,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-08"
  },
  "NCT06466291": {
    "nct_id": "NCT06466291",
    "brief_title": "Spanish Wilson Disease Registry",
    "official_title": "Registro de Enfermedad de Wilson en España",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [],
    "enrollment": 600,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-06-20"
  },
  "NCT03233191": {
    "nct_id": "NCT03233191",
    "brief_title": "Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer",
    "official_title": "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "PROCEDURE",
        "name": "Digital Mammography"
      },
      {
        "type": "PROCEDURE",
        "name": "Digital Tomosynthesis Mammography"
      },
      {
        "type": "OTHER",
        "name": "Laboratory Biomarker Analysis"
      }
    ],
    "enrollment": 108508,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-01-08"
  },
  "NCT04899310": {
    "nct_id": "NCT04899310",
    "brief_title": "A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia",
    "official_title": "A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "mRNA-3705"
      }
    ],
    "enrollment": 63,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-25"
  },
  "NCT06072781": {
    "nct_id": "NCT06072781",
    "brief_title": "A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer",
    "official_title": "A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "avutometinib"
      },
      {
        "type": "DRUG",
        "name": "Defactinib"
      },
      {
        "type": "DRUG",
        "name": "Pegylated liposomal doxorubicin"
      },
      {
        "type": "DRUG",
        "name": "Paclitaxel"
      },
      {
        "type": "DRUG",
        "name": "Letrozole"
      },
      {
        "type": "DRUG",
        "name": "Anastrozole"
      }
    ],
    "enrollment": 270,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-02"
  },
  "NCT06120140": {
    "nct_id": "NCT06120140",
    "brief_title": "Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib",
    "official_title": "A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Amivantamab IV"
      },
      {
        "type": "DRUG",
        "name": "Amivantamab SC"
      },
      {
        "type": "DRUG",
        "name": "Lazertinib"
      },
      {
        "type": "DRUG",
        "name": "Doxycycline"
      },
      {
        "type": "DRUG",
        "name": "Minocycline"
      },
      {
        "type": "DRUG",
        "name": "Clindamycin"
      },
      {
        "type": "DRUG",
        "name": "Chlorhexidine"
      },
      {
        "type": "OTHER",
        "name": "Noncomedogenic skin moisturizer"
      },
      {
        "type": "OTHER",
        "name": "Ruxolitinib"
      },
      {
        "type": "OTHER",
        "name": "Tacrolimus"
      }
    ],
    "enrollment": 300,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-29"
  },
  "NCT06082167": {
    "nct_id": "NCT06082167",
    "brief_title": "Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
    "official_title": "A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Zanzalintinib"
      },
      {
        "type": "DRUG",
        "name": "Zanzalintinib-matched Placebo"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Pembrolizumab"
      }
    ],
    "enrollment": 600,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-01-31"
  },
  "NCT06534892": {
    "nct_id": "NCT06534892",
    "brief_title": "An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study",
    "official_title": "A Phase 3b, Randomized, Open Label, Multicountry, Multi-center, Extension and Crossover Vaccination Study to Evaluate the Immunogenicity and Safety of Different Revaccination Schedules and Persistence of a Single Dose of the RSVPreF3 OA Vaccine in Adults Aged 60 Years and Above Who Participated in the RSV OA=ADJ-006 Study",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "RSVPreF3 OA vaccine"
      }
    ],
    "enrollment": 10356,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-17"
  },
  "NCT03567889": {
    "nct_id": "NCT03567889",
    "brief_title": "Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients",
    "official_title": "An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Daromun"
      },
      {
        "type": "PROCEDURE",
        "name": "Surgery"
      },
      {
        "type": "DRUG",
        "name": "Adjuvant therapy"
      }
    ],
    "enrollment": 186,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2023-11-30"
  },
  "NCT06615921": {
    "nct_id": "NCT06615921",
    "brief_title": "A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection",
    "official_title": "A Multi-country, Multi-center, Retrospective Chart Review to Describe the Use of Maribavir and Its Effectiveness in Patients With Post-Transplant Cytomegalovirus Infection/Disease",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "OTHER",
        "name": "No Intervention"
      }
    ],
    "enrollment": 150,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-04-27"
  },
  "NCT06455202": {
    "nct_id": "NCT06455202",
    "brief_title": "A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)",
    "official_title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "barzolvolimab"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Matching placebo"
      }
    ],
    "enrollment": 915,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-27"
  },
  "NCT06383390": {
    "nct_id": "NCT06383390",
    "brief_title": "The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)",
    "official_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Retatrutide"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 10000,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-25"
  },
  "NCT02362503": {
    "nct_id": "NCT02362503",
    "brief_title": "Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients",
    "official_title": "A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "BMS-663068"
      },
      {
        "type": "OTHER",
        "name": "Placebo"
      }
    ],
    "enrollment": 371,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-05"
  },
  "NCT05535946": {
    "nct_id": "NCT05535946",
    "brief_title": "ABTECT - Maintenance",
    "official_title": "A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "ABX464"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 1050,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-08-07"
  },
  "NCT04965493": {
    "nct_id": "NCT04965493",
    "brief_title": "A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)",
    "official_title": "A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Pirtobrutinib"
      },
      {
        "type": "DRUG",
        "name": "Venetoclax"
      },
      {
        "type": "DRUG",
        "name": "Rituximab"
      }
    ],
    "enrollment": 600,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-02"
  },
  "NCT05018585": {
    "nct_id": "NCT05018585",
    "brief_title": "A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes",
    "official_title": "A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults With Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®"
      },
      {
        "type": "DIETARY_SUPPLEMENT",
        "name": "Colecalciferol 2000 IU"
      },
      {
        "type": "BIOLOGICAL",
        "name": "Placebo"
      }
    ],
    "enrollment": 330,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-01"
  },
  "NCT06378632": {
    "nct_id": "NCT06378632",
    "brief_title": "AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM",
    "official_title": "An International Multi-center Observational, Single-arm, Blinded Study to Assess the Performance of the Cordio HearO System",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "DEVICE",
        "name": "Hearo App"
      }
    ],
    "enrollment": 500,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-26"
  },
  "NCT02308085": {
    "nct_id": "NCT02308085",
    "brief_title": "Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer",
    "official_title": "A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy",
    "overall_status": "ACTIVE_NOT_RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "OTHER",
        "name": "Endocrine therapy interruption"
      }
    ],
    "enrollment": 518,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-05"
  },
  "NCT05362370": {
    "nct_id": "NCT05362370",
    "brief_title": "Stryker PEEK Customized Implant: A Prospective Post Market Follow Up to Evaluate Safety, Performance and Effectiveness",
    "official_title": "Stryker PEEK Customized Implant: A Prospective Post Market Follow Up to Evaluate Safety, Performance and Effectiveness",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "DEVICE",
        "name": "Stryker's PEEK Customized Implant"
      }
    ],
    "enrollment": 110,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-15"
  },
  "NCT04884815": {
    "nct_id": "NCT04884815",
    "brief_title": "A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease",
    "official_title": "An Operationally Seamless Phase 1/2/3 Study Consisting of a Safety and Dose-finding Phase 1/2 and Randomized, Open-label, Active-controlled Phase 3 to Evaluate UX701 AAV Gene Therapy in Adults With Wilson Disease",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "GENETIC",
        "name": "UX701"
      },
      {
        "type": "DRUG",
        "name": "Standard of Care (SOC)"
      }
    ],
    "enrollment": 82,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-20"
  },
  "NCT05653349": {
    "nct_id": "NCT05653349",
    "brief_title": "Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)",
    "official_title": "A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "BIOLOGICAL",
        "name": "Ianalumab"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      },
      {
        "type": "DRUG",
        "name": "Corticosteroids"
      }
    ],
    "enrollment": 225,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-27"
  },
  "NCT05639400": {
    "nct_id": "NCT05639400",
    "brief_title": "Thoraflex Hybrid and Relay Extension Post-Approval Study",
    "official_title": "Thoraflex Hybrid and Relay Extension Post-Approval Study",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "DEVICE",
        "name": "Thoraflex Hybrid"
      },
      {
        "type": "DEVICE",
        "name": "RelayPro NBS"
      }
    ],
    "enrollment": 200,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-13"
  },
  "NCT04396236": {
    "nct_id": "NCT04396236",
    "brief_title": "A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine",
    "official_title": "Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Lasmiditan"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 1633,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-07-03"
  },
  "NCT05849298": {
    "nct_id": "NCT05849298",
    "brief_title": "A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC",
    "official_title": "An International Prospective Open-label, Multi-center, Randomized, Non-comparative Phase II Study of Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) Alone and Lutetium [177Lu] Vipivotide Tetraxetan (AAA617) in Combination With Androgen Receptor Pathway Inhibitors in Patients With PSMA PET Scan Positive Castration-Resistant Prostate Cancer",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "AAA617"
      },
      {
        "type": "DRUG",
        "name": "AAA517"
      },
      {
        "type": "DRUG",
        "name": "Piflufolastat F 18"
      },
      {
        "type": "DRUG",
        "name": "ARPI"
      },
      {
        "type": "DRUG",
        "name": "ADT"
      },
      {
        "type": "OTHER",
        "name": "Best supportive care"
      }
    ],
    "enrollment": 120,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-05-29"
  },
  "NCT04849728": {
    "nct_id": "NCT04849728",
    "brief_title": "A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )",
    "official_title": "A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "IVA337"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 1000,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2024-01-26"
  },
  "NCT06671483": {
    "nct_id": "NCT06671483",
    "brief_title": "A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines",
    "official_title": "A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Zasocitinib"
      },
      {
        "type": "DRUG",
        "name": "Active Comparator"
      },
      {
        "type": "DRUG",
        "name": "Placebo"
      }
    ],
    "enrollment": 1088,
    "diseases": [
      {
        "orpha_code": "905",
        "disease_name": "Wilson disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-17"
  },
  "NCT06934681": {
    "nct_id": "NCT06934681",
    "brief_title": "Exercise to Fight Obesity",
    "official_title": "Impact of a Structured Physical Exercise Program on Body Composition in Morbid Obesity: A Randomized Controlled Trial",
    "overall_status": "RECRUITING",
    "study_type": "INTERVENTIONAL",
    "phases": [
      "NA"
    ],
    "interventions": [
      {
        "type": "BEHAVIORAL",
        "name": "Usual Care Group"
      },
      {
        "type": "BEHAVIORAL",
        "name": "Controlled exercise with telerehabilitation"
      }
    ],
    "enrollment": 72,
    "diseases": [
      {
        "orpha_code": "909",
        "disease_name": "Cerebrotendinous xanthomatosis"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-06-04"
  },
  "NCT05718700": {
    "nct_id": "NCT05718700",
    "brief_title": "Study of Bulevirtide in Participants With Chronic Hepatitis D Infection",
    "official_title": "A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection",
    "overall_status": "RECRUITING",
    "study_type": "OBSERVATIONAL",
    "phases": [],
    "interventions": [
      {
        "type": "DRUG",
        "name": "Bulevirtide"
      }
    ],
    "enrollment": 170,
    "diseases": [
      {
        "orpha_code": "99718",
        "disease_name": "Leber plus disease"
      }
    ],
    "locations_spain": true,
    "last_update": "2025-03-21"
  }
}